

CURRICULUM VITAE

NAME: Lee S. Schwartzberg, M.D., F.A.C.P.

OFFICE ADDRESS: West Cancer Center
7945 Wolf River Blvd.
Germantown, TN 38138
901-683-0055
www.westcancercenter.org

West Cancer Center
7668 Airways Blvd.
Southaven, MS 38671

West Cancer Center
1588 Union Avenue
Memphis, TN 38104

The West Clinic
1500 West Poplar, Suite 304
Collierville, TN 38017

West Cancer Center
240 Grandview Drive
Brighton, TN 38011

The West Clinic
401 Alcorn Drive, Ste. #2C
Corinth, MS 38834

EDUCATION:

Undergraduate: State University of New York at Buffalo,
Buffalo, NY, 1969-1973, B.A., June, 1973

Graduate: State University of New York at Buffalo,
Buffalo, NY, 1973-1974, M.S., September, 1974

Medical School: New York Medical College, Valhalla, NY 1974-1976
Research/Dept. of Hematology / Oncology

New York Medical College, Valhalla, NY 1976-1980,
M.D., June, 1980

Internship: Internal Medicine, North Shore University Hospital
Manhasset, NY, 1980-1981

EDUCATION
(Cont'd)

Residency:	Internal Medicine, North Shore University Hospital, Manhasset, NY, 1981-1983 Chief Resident in Medicine, Memorial Sloan- Kettering Cancer Center, New York, NY, 1984-1985
Fellowship:	Medical Oncology/Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, 1983-1984, 1985-1987
MILITARY SERVICE:	None
BOARD CERTIFICATION:	National Board of Medical Examiners, 1981 Internal Medicine, 1983 Medical Oncology, 1985 Hematology, 1986
MEDICAL LICENSURE:	New York State, 1981 Tennessee State, 1987 Mississippi State, 1989 Arkansas State, 2002
PROFESSIONAL SOCIETY MEMBERSHIPS:	American Society of Clinical Oncology American Society of Hematology Society for Biological Therapy Southern Medical Association American Association for the Advancement of Science American Society for Blood and Marrow Transplantation American Society of Breast Disease
PROFESSIONAL COMMITTEES & ACTIVITIES:	Charter Member, Memorial Hospital Institutional Ethics Committee, 1985-1987 Cancer Committee, Baptist Memorial Hospital 1988 - 1998 Principal Investigator, National Biotherapy Study Group, 1990-1993 Board of Directors, American Cancer Society, Memphis/Shelby County Unit, 1990 – 1996

PROFESSIONAL
COMMITTEES &
ACTIVITIES:
(Cont'd)

Research Director, West Cancer Center,
1990 – Present

Chairman, Committee on Professional Education,
American Cancer Society, Memphis/Shelby County
Unit, 1991 – 1994

Institutional Review Board (Patient Participation
Committee), Baptist Memorial Hospital,
1992 - 2004

Chairman, Breast Cancer Research Committee,
Baptist Cancer Institute, 1994 – 2007

President, American Cancer Society,
Memphis / Shelby County Unit, 1994-1995

Principal Investigator, Baptist Cancer Institute
Community Clinical Oncology Program, (BCI-CCOP)
1995 - 2000

Executive Committee, Baptist Cancer Institute
1995 – 2000

Medical Director, West Cancer Center
2000 - Present

Institute of Medicine's Committee on Psychosocial Services to Cancer
Patients/Families in a Community Setting, 2007

PRACTICE
PROFESSIONAL
EXPERIENCE:

Private Practice, Hematology and Medical Oncology
Medical Director, The West Clinic, P.C. d/b/a West Cancer Center
7945 Wolf River Blvd., Germantown, TN 38138
July, 1987 - Present

Medical Director, Myelosuppression Unit
6019 Walnut Grove Road, Memphis, TN
Baptist Memphis Hospital, 1996 - 2009

Medical Director, C.A.R.E.S. (Cancer Assessment, Risk,
Evaluation and Surveillance) Program
Baptist Memorial Hospital
899 Madison Avenue, Memphis, TN 1997 - 2009

Chief Medical Officer, SOS (Supportive Oncology Services)
1770 Kirby Parkway, Suite 400
Memphis, TN 38138 2002 - 2009

PRACTICE
PROFESSIONAL
EXPERIENCE:
(Cont'd)

President & CMO, ACORN Research, LLC
1770 Kirby Parkway, Suite 400
Memphis, TN 38138 2002 - 2014

President & CMO, Vector Oncology, LLC
6555 Quince, Suite 400
Memphis, TN 38119 2014 - Present

Editor-in-Chief, *Community Oncology Journal*
Elsevier Oncology
Huntington, NY 2004 – 2011

Editor-in-Chief, OncologySTAT
Elsevier Oncology
Huntington, NY 2007 – Present

National Comprehensive Cancer Network
Board Member, 2012

HOSPITAL
APPOINTMENTS:

Active Attending Staff, Baptist Memorial
Hospital, Memphis, TN

Associate Staff, Baptist Memorial Hospital-
Desoto, Southaven, MS

Consulting Staff, St. Francis Hospital
Memphis, TN

Consulting Staff, Germantown Methodist
Memphis, TN

ACADEMIC
APPOINTMENTS:

Fellow in Medicine, Cornell University
Medical College, 1983-1984, 1985-1987

Clinical Instructor, Cornell University
Medical College, 1984-1985

Clinical Instructor, University of Tennessee
School of Medicine, 1987-1989

Clinical Assistant Professor, University of
Tennessee School of Medicine, 1989-1993

Clinical Associate Professor, University of
Tennessee School of Medicine, 1993 – 1999

ACADEMIC
APPOINTMENTS
(cont'd)

Clinical Professor, University of Tennessee School of Medicine, 1999-
present

Division Chief, Hematology/Oncology, University of Tennessee School
of Medicine, Jan 2012 - Present

HONORS
AND AWARDS:

Alpha Omega Alpha, 1979
American Cancer Society Clinical Fellowship, 1983-1984
National Research Service Award, 1985-1987
Lacker Fund Award, 1985-1987
Clinical Scholar Fellowship, 1986-1987
American Cancer Society Mem/Shelby Co. Unit President, 1994-1995
American Cancer Society Henry G. Rudner Memorial Award
Presidents Award, American Cancer Society, 1996
Community Clinical Oncology Program (CCOP) Award,
1996-1999
Fellow of the American College of Physicians-American Society
of Internal Medicine (ACP-ASIM), 2000
Memphis Business Journal, Health Care Heroes, 2001, 2003, 2011
Strathmore's WHO'S WHO Professional of the Year 2005 - 2006 in
Hematology/Oncology
American College of Physicians TENNESSEE CHAPTER Volunteerism
& Community Service Award, 2007
Castle Connolly Top Doctors, 2007-2011
American Cancer Society, Shelby County Division, Physician Honoree
of the Year, 2008
ASCO 2010 Clinical Trials Participation Award

INVITED
PRESENTATIONS:

Available Upon Request

BIBLIOGRAPHY

LEE S. SCHWARTZBERG, M.D.

ABSTRACTS

1. Schwartzberg L, Braverman A. Globin chain catabolism in mild and severe B. Thalassemia. Clin Res 24:295, 1976.
2. Schwartzberg L, Nahmias N, Gee T, Andreeff M, Clarkson B. Treatment of central nervous system relapse in adult acute lymphoblastic leukemia. Proc Amer Soc Clin Oncol 5:160, 1986.
3. West W, Tauer K, Schwartzberg L, Marshall G, Orr D, Oldham R. Constant infusion recombinant interleukin-2 (rIL-2) in the treatment of advanced renal carcinoma. Proc ASCO; 7:A479, 1988. (Presented)

CURRICULUM VITAE

Lee S. Schwartzberg, M.D.

Page 6

4. Marshall G, Tauer K, Schwartzberg L, Lee P, Price J, Holbert J, West W. In vivo and in vitro recombinant interleukin-2 (rIL-2) potentiates in vitro heteroconjugate antibody (HC)-targeted cellular cytotoxicity. Proc Annu Meet Am Assoc Cancer Res; 29:A874, 1988.
5. Schwartzberg L, Tauer K, Birch R, Orr D, Lewis M, Oldham R, West W. Phase I study of sequential recombinant tumor necrosis factor (rTNF) and recombinant interleukin-2 (rIL-2) in patients with advanced malignancy. Proc ASCO; 8:711, 1989. (Presented)
6. Schwartzberg L, West W, Birch R, Tauer K, Lee P, Hazelton B. High-dose cyclophosphamide (HD-CTX) or etoposide (HDVP-16) as mobilization chemotherapy for peripheral blood stem cell (PBSC) harvest (Meeting abstract) Proc Am Soc Hem; Blood;76A2247, 1990.
7. Dillman R, Church C, Barth N, Oldham R, Schwartzberg L, Arnold J, Birch R, and West W. High-dose continuous infusion IL-2 in 693 cancer patients - Experience of the National Biotherapy Study Group (NBSG). Proc ASCO; 10:A711, 1991. (Presented)
8. Schwartzberg L, West W, Fyfe G, Tauer K, Zimmerman R, Arnold J. A phase I study of recombinant interleukin-2 (rIL-2) in advanced malignancy: Modification of dosing to emulate the pharmacokinetics of polyethylene glycol-modified rIL-2 (PEG-IL-2). Proc ASCO; 10A241, 1991. (Presented)
9. Schwartzberg L, West W, Birch R, Tauer K, Lee P, Altemose R. Mobilized peripheral blood stem cells (PBSC) alone for hematologic reconstitution after high-dose chemotherapy for advanced malignancy. Proc ASCO; 10A1131, 1991. (Presented)
10. Schwartzberg L, West W, Muscato J, Monaghan G, Kalman L, Birch R. G-CSF improves peripheral blood stem cell (PBSC) mobilization and hematologic reconstitution after high-dose chemotherapy. Proc ASCO; 11A337, 1992.
11. Schwartzberg L, Tauer K, West W, Wittlin F, Magee M, Raefsky E, Birch R. Simultaneous remission induction and mobilization of peripheral blood stem cells (PBSC) in recurrent/refractory, non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol; 11A1134, 1992.
12. West W, Schwartzberg L, Citron P, Schnell F, Blanco R, Birch R. High dose Cyclophosphamide-based mobilization of peripheral blood stem cells: experience with outpatient delivery. (Meeting Abstract) Proc Am Soc Clin Oncol; 11A1404, 1992.
13. Schwartzberg L, West W, Tauer K, Altemose R., George, C., Birch, R. Cyclophosphamide, Etoposide, Cisplatin plus G-CSF (CEP+G) for peripheral blood stem cell (PBSC) mobilization. (Meeting Abstract) Proc Am Soc Clin Oncol; 11A1405, 1992.
14. Schwartzberg L, West W, Birch R, Muscato J, Wittlin F, Blanco R, Hazelton B. G-CSF improves peripheral blood stem cells (PBSC) mobilization and hematologic reconstitution after high-dose chemotherapy. International Journal of Cell Cloning 10 (suppl 1): 193, 1992. (Presented)

CURRICULUM VITAE

Lee S. Schwartzberg, M.D.

Page 7

15. Schwartzberg L, Birch R, and West W. Tandem high-dose chemotherapy with peripheral blood stem cell (PBSC) support in refractory/recurrent lymphoma. (Meeting abstract) Proc Am Soc Hem; Blood 80A1888, 1992.
16. Schwartzberg L, Birch R, West W. Three phase escalating dose-intense chemotherapy (CT) with peripheral blood stem cell (PBSC) support for patients with metastatic breast cancer (MBC). (Meeting Abstract) Breast Cancer Symposium, 1992.
17. West W, Schwartzberg L, Tauer K, George C, Muscato J, Raefsky E, Birch R. CA 15.3 patterns and outcome of high-dose chemotherapy in patients with initial presentation of metastatic carcinoma of the breast. (Meeting abstract) Proc Am Soc Clin Oncol; J Clin Oncol; 12A169, 1993.
18. Schwartzberg L, West W, Birch R, Tauer K, Kalman L, Magee M, Muscato J, Wittlin F, Blanco R, Harden E. Multi-center trial of dose escalating induction, consolidation and triple alkylator intensification in newly diagnosed metastatic breast cancer (MBC). (Meeting abstract) Proc Am Soc Clin Oncol; 12A175, 1993.
19. Schwartzberg L, West W, Birch R, Heffernan M, Tauer K, Kalman L, Middleman E, Pendergrass K, Leff R. Randomized prospective trial \pm pretreatment with GM-CSF prior to high-dose Cyclophosphamide, Etoposide, and Cisplatin + G-CSF. (Meeting Abstract) Proc Am Soc Clin Oncol; J Clin Oncol; 12A1568, 1993.
20. West W, Birch R, Schwartzberg L, Altemose R, George C. Dose intensive chemotherapy can be safely administered in an outpatient setting: results of a multicenter trial. (Meeting Abstract) Proc Am Soc Clin Oncol; J Clin Oncol; 12A1569, 1993.
21. Birch R, West W, and Schwartzberg L. A randomized comparison of the effect of G-CSF on the recovery of patients receiving peripheral blood stem cells (PBSC) after high-dose chemotherapy for breast cancer (Meeting Abstract) 3rd International Symposium on PBSC, Bordeaux, France, 1993.
22. Schwartzberg L, Birch R, Heffernan M, and West W. Mobilized peripheral blood stem cell (PBSC) harvest in 1,017 patients (PTS): the Response Technologies' experience. (Meeting Abstract) 3rd International Symposium on PBSC, Bordeaux, France, 1993. (Presented)
23. Schwartzberg L, Birch R, Heffernan M, and West W. G-CSF is an effective supportive modality in peripheral blood stem cell (PBSC) transplantation. (Meeting Abstract) Proc Am Soc Hematol; Blood; 82A1131, 1993.
24. Schwartzberg L, Heffernan M, Birch R, and West W. Comparison of different G-CSF schedules in conjunction with cyclophosphamide, etoposide, and cisplatin (HD CEP) for peripheral blood stem cell (PBSC) mobilization. (Meeting Abstract) Proc Am Soc Hematol; Blood; 82A2548, 1993.
25. Schwartzberg L, Birch R, Hazelton B, Tauer K, Kalman L, Ross A, Raefsky E, Wittlin F, Schnell F, and West W. High-dose chemotherapy with peripheral blood stem cell (PBSC) support for high risk stage II and stage III breast cancer (Meeting Abstract) Proc Am Soc Clin Oncol; J Clin Oncol; 13A192, 1994.

CURRICULUM VITAE

Lee S. Schwartzberg, M.D.

Page 8

26. Schwartzberg L, Birch R, Weaver C, and West W. The effect of varying durations of granulocyte colony stimulating factor (G-CSF) on neutrophil engraftment and supportive care following peripheral blood progenitor cell (PBSC) infusion. (Meeting Abstract) Proc Am Soc Hematol; Blood, 84A354, 1994.
27. Weaver C, Birch R, Schwartzberg L, Palmer P, and West W. CD34 content of peripheral blood progenitor cells (PBPC) is the single most powerful predictor of recovery kinetics in patients receiving myeloablative high-dose chemotherapy (HDC) and PBPC infusion. (Meeting Abstract) Proc Am Soc Hematol; Blood; 84A1388, 1994.
28. Weaver C, Hazelton B, Ross A, and Schwartzberg L. The incidence of tumor cell contamination in peripheral blood progenitor cell (PBPC) collections in patients with breast cancer. (Meeting Abstract) Proc Am Soc Hematol; Blood; 84A1389, 1994. (Presented)
29. Allen C, Hazelton B, Weaver C, Birch R, Schwartzberg L, West W. A clinically applicable flow cytometric method can predict engraftment potential in PBPC products. (Meeting Abstract) Proc 10th Annual Meet Clin Appl Cytometry; 54;21, 1995.
30. Palmer P, Schwartzberg L, Birch R, West W, and Weaver C. High-dose melphalan (Mel) \pm mitoxantrone (Mito) with peripheral blood progenitor cell (PBPC) support as a component of initial treatment of patients with advanced ovarian cancer. (Meeting Abstract) Proc Am Soc Clin Oncol; J Clin Oncol; 14A991, 1995.
31. Schwartzberg L, Birch R, Weaver C, Palmer P, Tauer K, McAneny B, Kalman L, and West W. Prognostic factors after high-dose chemotherapy (HDC) for high risk stage II and III breast cancer. (Meeting Abstract) Proc Am Soc Clin Oncol; J Clin Oncol; 14A114, 1995.
32. Weaver C, Hazelton B, Ross A, and Schwartzberg L. The incidence of tumor cell contamination in peripheral blood progenitor cell (PBPC) collections in patients with breast cancer. (Meeting Abstract) ISHAGE 2nd International Meeting; J Hematother; 4A43, 1995. (Presented)
33. Weaver C, Tauer K, O'Rourke M, Rhinehart S, Pendergrass K, Schwartzberg L, and Li W. A randomized phase IIB trial comparing high-dose busulfan, melphalan and thiotepa (BuMelT) with carmustine, etoposide, cytosine arabinoside and cyclophosphamide (BEAC) followed by peripheral blood progenitor cell (PBPC) infusion in patients with relapsed lymphoid malignancies. (Meeting Abstract) Proc Am Soc Hematol; Blood; 86A3880, 1995.
34. Weaver C, Wittlin F, Lewis M, Schwartzberg L, Li W, and Palmer P. A phase I trial of high-dose melphalan, mitoxantrone, and carboplatin in patients with ovarian and breast cancer. (Meeting Abstract) Proc Am Soc Hematol; Blood; 86A3879, 1995.
35. Weaver C, Li W, and Schwartzberg L. Intermediate dose cyclophosphamide, etoposide and rhG-CSF for mobilization of peripheral blood progenitor cells (PBPCs) in 497 patients. (Meeting Abstract) Proc Am Soc Hematol; Blood; 86A1603, 1995.
36. Hazelton B, Birch R, Schwartzberg L, West W, Dolan C. CD34 yield alone is sufficient to determine adequacy of peripheral blood progenitor cell products. (Meeting Abstract) Am Assoc Blood Banks, 1996.

37. Schwartzberg L, Birch R, Weaver C, Tauer K, Kalman L, Feinberg B, and West W. Neoadjuvant chemotherapy with or without paclitaxel and high-dose chemotherapy (HDC) with peripheral blood progenitor cell (PBPC) support for locally advanced breast cancer (LABC). (Meeting Abstract) Proc Am Soc Clin Oncol; J Clin Oncol; 15A160, 1996.
38. Weaver C, Schwartzberg L, Greco F, Hainsworth J, Tauer K, Getaz P, Palmer P, Li W, Birch R, and West W. An intent-to-treat analysis of a multi-institution phase II trial of high-dose chemotherapy (HDC) in patients with newly diagnosed stage IV breast cancer. (Meeting Abstract) Proc Am Soc Clin Oncol; J Clin Oncol; 15A989, 1996. (Presented)
39. Weaver C, Hazelton B, Palmer P, Li W, Birch R, Alberico T, West W, and Schwartzberg L. A randomized dose finding study of filgrastim for mobilization of peripheral blood progenitor cells (PBPCs). (Meeting Abstract) Proc Am Soc Clin Oncol; J Clin Oncol; 15A990, 1996.
40. Schwartzberg L, Birch R, and Weaver C. Prospective randomized comparison of high vs. intermediate dose cyclophosphamide based mobilization therapy for mobilization of peripheral blood stem cells (PBSC). (Meeting Abstract) Proc Am Soc Hematol; Blood; 1996. (Presented)
41. Weaver C, Schwartzberg L, Upton S, Birch R, and Buckner C. Interim analysis of a randomized phase II trial comparing high-dose busulfan, melphalan, and thiotepa (BuMelT) with carmustine, etoposide, cytosine arabinoside and cyclophosphamide (BEAC) followed by peripheral blood stem cell (PBSC) infusion in patients with relapsed Hodgkin's disease (HD). (Meeting Abstract) Proc Am Soc Hematol; Blood; 1996. (Presented)
42. Weaver C, Schwartzberg L, Zhen B, Hazelton B, and Buckner C. Engraftment in patients with PBSC having low CD34+ cell content. (Meeting Abstract) Proc Am Soc Hematol; Blood; 1996.
43. Schwartzberg L, Birch R, Andrews C, Burke L, Hazelton B, Murphy M, Buckner C, and Weaver C. A new dual chamber implantable injection system for long term cancer chemotherapy and apheresis of peripheral blood stem cells. (Meeting Abstract) Proc Am Soc Hematol; Blood; 1996. (Presented)
44. Schwartzberg L, Zhen B, Buckner C, Moss T, Murphy M, Birch R, and Weaver C. Low incidence of tumor cell contamination in peripheral blood stem cell (PGSC) collections of patients (pts) with stage I-III breast cancer. (Meeting Abstract) Proc Am Soc Clin Oncol; J Clin Oncol; 16A416;1997. (Presented)
45. Dillman R, Nayak S, Barth N, DeLeon C, Schwartzberg L, Spittler L, O'Connor A, Beutel L, Church C. Irradiated autologous melanoma cells from short-term tissue culture as vaccines for patients with metastatic melanoma. (Meeting Abstract) Proc Am Soc Clin Oncol; 17A1697;1998.
46. Schwartzberg L, Birch R, Weaver C, Campos L, Buckner C. High pathological complete response (CR) rate to sequential doxorubicin and paclitaxel primary chemotherapy for locally advanced breast cancer (LABC). (Meeting Abstract) Proc Am Soc Clin Oncol, 17A431;1998. (Presented)

CURRICULUM VITAE

Lee S. Schwartzberg, M.D.

Page 10

47. Burgess J, Mills B, Griffith M, Mansour V, Weaver C, Schwartzberg L, Snyder E, Krause D, Yanovich S, Prilutskaya M, Moss T. Reduction of breast cancer cells in peripheral blood stem cell products by positive selection of CD34+ cells. (Meeting Abstract) ISHAGE 5th International Meeting, J Hematother; 1998.
48. Schwartzberg L, Birch R, Weaver C, Smith S, Buckner C. Preliminary Results of a Phase III Randomized Trial Comparing Simultaneous to Sequential Dose-Dense Administration of Doxorubicin and Docetaxel in Metastatic Breast Cancer (MBC). (Meeting Abstract), 21st Annual San Antonio Breast Cancer Symposium, 1998. (Presented)
49. Feldman E, Kalaycio M, Schulman P, Frankel S, Weiner G, Schwartzberg L, Velez-Garcia E, Jurcic J, Scheinberg D, Wedel N. Humanized Monoclonal Anti-CD33 Antibody HUM195 in the Treatment of Relapsed/Refractory Acute Myelogenous Leukemia (AML): Preliminary Report of a Phase II Study (Meeting Abstract) J Clin Oncol; 18A12; 1999.
50. Schwerkoske J, Schwartzberg L, Weaver C, Schwertschlag U, Goodfellow J, Bedrosian C. A Phase I Double-Masked, Placebo-Controlled Study to Evaluate Tolerability of Neumega® (rhIL-11; Oprelvekin) to Reduce Mucositis in Patients with Solid Tumors or Lymphoma Receiving High-Dose Chemotherapy (CT) with Autologous Peripheral Blood Stem Cell Reinfusion (PBSCT). J Clin Oncol, 18A2256; 1999.
51. Coluzzi P, Schwartzberg L, Simmonds M, Charapata S, Gay M. Oral Transmucosal Fentanyl Citrate (OTFC) Provides Superior Analgesia at 15, 30, 45 and 60 Minutes Post Administration Compared to Immediate Release Morphine (IRM) in treatment of Cancer Related Breakthrough Pain (BTP). (Meeting Abstract) American Pain Society, San Diego, CA;1999.
52. Dillman R, Barth N, DeLeon C, O'Conner A., Schwartzberg L, Spitler L, Mahdavi K, Garfield D, Beutel L, Nayak S. Short-Term Autologous Tumor Cell Lines For The Active Specific Immunotherapy of Metastatic Melanoma. (Meeting Abstract) International Conference on Advances in Cancer Immunotherapy, Princeton, NJ; 1999.
53. Glaspy J, Jadeja J, Justice G, Kessler J, Richards D, Schwartzberg L. The ARANESP 980290 Study Group, O'Byrne J, Armstrong S, Colowick A. Randomized . Active-Controlled, Phase 1/2, Dose-Escalation Study of NESP Administered Weekly and Every 2 Weeks in Patients with Solid Tumors (Meeting Abstract) J Clin Oncol ; 20A1546; 2001.
54. Fortner B, Stolshek B, Schwartzberg L, Tauer K, Okon T. Decline in absolute neutrophil count (ANC) is associated with lower quality of life (QoL) in cancer patients receiving docetaxel. (Meeting Abstract) Proc Am Soc Clin Oncol; 21A:2808; 2002.
55. Okon T, Fortner B, Schwartzberg L, Tauer K. Quality of life (QoL) in patients with grade IV chemotherapy-induced neutropenia (CIN). (Meeting Abstract) Proc Am Soc Clin Oncol; 21A:2920; 2002.
56. Tauer K, Schwartzberg L, Fortner B, Patterson S, Wiseman B, Lee G, Blackburn S, Steele V. A novel, self-funded, support mechanism in an outpatient community cancer clinic. (Meeting Abstract) Proc Am Soc Clin Oncol; 21A:2864; 2002.

57. Houts A, Fortner B, Okon T, Tauer K, Wheeler B, Weir A, Schwartzberg L. Reliability and validity of the cancer care monitor (CCM). (Meeting Abstract) Proc Am Soc Clin Oncol; 21A:1002; 2002.
58. Fortner B, Durrence H, Mao Q, Schwartzberg L, Houts A. Development, reliability and validity of the cancer care monitor neutropenia index (CCM-N). (Meeting Abstract) Proc Am Soc Hematol; Blood; 98A3446, 2002.
59. Schwartzberg L, Fortner B, Stolshek B, Tauer K, Durrence H, Okon T, Houts A. Chemotherapy-induced neutropenia (CIN) is associated with lower quality of life (QoL) in patients (pts) with cancer. Proc Am Soc Hematol; Blood; 98A5600, 2002.
60. Fortner B, Mao Q, Stolshek B, Schwartzberg L. Association of IV antibiotic use and hospitalization with filgrastim (F) and pegfilgrastim (PEGF) utilization in a community oncology clinic sample. Am Jnl Hlth Syst Pharm; 60(20):2139, 2003.
61. Fortner B, Schwartzberg L, Ashley J, Durrence H, Tauer K, Wheeler B, Mao Q. A single pegfilgrastim (PEGF) dose per cycle maintains neutrophil counts after docetaxel (DOC) and gemcitabine (GEM) chemotherapy for advanced non-small cell lung cancer (NSCLC). (Meeting Abstract) Proc Am Soc Clin Oncol; 22A:2799; 2003.
62. Houts A, Durrence H, Tauer K, Schwartzberg L, Fortner B. Validation of physical symptom items of the cancer care monitor. (Meeting Abstract) Proc Am Soc Clin Oncol; 22A:2214; 2003.
63. Tauer K, Mao Q, Schwartzberg L, Fortner B. Minimal doses and delayed timing of filgrastim (F) may impact patient outcomes as compared to pegfilgrastim (PEGF). (Meeting Abstract) Proc Am Soc Clin Oncol; 22A:3147; 2003.
64. Okon T, Tauer K, Zhu L, Moore K, Schwartzberg L, Fortner V. Drug reimbursement needs to include all costs beyond drug acquisition, including human resource utilization. (Meeting Abstract) Proc Am Soc Clin Oncol; 22A:2218; 2003.
65. Peterson M, Mao Q, Schwartzberg L, Fortner V. Higher rates of early response needed with epoetin alfa (EPO) and darbepoetin alfa in the community setting. (Meeting Abstract) Proc Am Soc Clin Oncol; 22A:3149; 2003.
66. Durrence H, Houts A, Schwartzberg L, Fortner V. Patients with grades III (G3) and IV (G4) chemotherapy-induced neutropenia (CIN) have greater physical and psychological symptom burden. (Meeting Abstract) Proc Am Soc Clin Oncol; 22A:3115; 2003.
67. Fortner V, Durrence H, Houts A, Tauer K, Schwartzberg L. Development, reliability, and validity of the cancer care monitor anemia index (CCMA) in cancer patients receiving chemotherapy. (Meeting Abstract) Proc Am Soc Hematol; Blood; 99A707, 2003.
68. Fortner B, Durrence H, Houts A, Schwartzberg L. Validation of the functional assessment of cancer therapy-neutropenia (FACT-N) and the cancer care monitor-neutropenia index (CCM-N). (Meeting Abstract) Proc Am Soc Hematol; Blood; 99A1807, 2003.

69. Schwartzberg L, Tauer K, Durrence H, Mao Q, Houts A, Fortner B. Chemotherapy-induced anemia (CIA) occurs frequently in women receiving adjuvant/neoadjuvant chemotherapy and impacts quality of life (QoL). (Meeting Abstract) Proc Am Soc Hematol; Blood; 99A5773, 2003.
70. Fortner B, Tauer K, Zhu L, Schwartzberg L. The impact of anemia treatment visits on the patient and their caregiver. (Meeting Abstract) 16th International MASCC/ISOO Symposium: Supportive Care in Cancer. Abstract 223.125001, 2004.
71. Schwartzberg L, Fortner B, Houts A. Gender differences in cancer patients with mild anemia: symptom burden and quality of life. (Meeting Abstract) 16th International MASCC/ISOO Symposium: Supportive Care in Cancer. Abstract 221.125001, 2004.
72. Fortner B, Houts A, Lipinski D, Tauer K, Schwartzberg L. Utility of the cancer care monitor to identify depression and anxiety in community oncology. 16th International MASCC/ISOO Symposium: Supportive Care in Cancer. Abstract 254.125001, 2004.
73. Fortner B, Moore K, Tauer K, Templeton D, Okon T, Johnson G, Schwartzberg L. Baseline evaluation of the AIM Higher Initiative: Patient interview data. 16th International MASCC/ISOO Symposium: Supportive Care in Cancer. Abstract 323.125001, 2004.
74. Schwartzberg L, Tauer K, Fortner B. Dose dense chemotherapy (DDC) supported by pegfilgrastim (PEG) and an erythropoietic agent (EA) in operable breast cancer. Abstract presented at the 27th Annual San Antonio Breast Cancer Symposium, 2004 (Abstract 551118).
75. Fortner B, Tauer K, Zhu L, Schwartzberg L. The impact of anemia and neutropenia treatment visits on patients and their caregiver. Abstract presented at the 27th Annual San Antonio Breast Cancer Symposium, 2004 (Abstract 551300).
76. Schwartzberg L, Fortner B, Houts A. Clinical significance of symptom burden and quality of life decrement in cancer patients with mild anemia. (Meeting Abstract) Proc Am Soc Hematol; Blood; 104A5305, 2004.
77. Johnson G, Schwartzberg L, Tauer K, Mao Q, Fortner B. Hematological toxicities, symptom burden, and quality of life (QoL) adjuvant and neoadjuvant breast cancer patients receiving dose dense chemotherapy (DDC). Abstract presented at the 8th National Conference on Cancer Nursing Research, 2005 (Abstract 354).
78. Johnson G, Schwartzberg L, Fortner B. Methodology challenges and solutions for conducting quality of life research. Abstract presented at the 8th National Conference on Cancer Nursing Research, 2005 (Abstract 326).
79. Johnson G, Fortner B, Moore K, Tauer K, Zhu L, Schwartzberg L. AIM Higher Working Group3. Baseline evaluation of assessment, information, and management patterns in a national quality improvement project. ONS Spring Conference, 2005 (Abstract 669).
80. Schwartzberg L, Houts A, Fortner B. Mild anemia is associated with greater symptom burden (SB) and reduced quality of life (QoL) in cancer patients. Abstract submitted to ASCO, 2005 (Abstract 8123).

CURRICULUM VITAE

Lee S. Schwartzberg, M.D.

Page 13

81. Fortner B, Houts A, Johnson G, Schwartzberg L. A prospective investigation of chemotherapy-induced neutropenia (CIN) and quality of life (QoL). Abstract submitted to ASCO, 2005 (Abstract 8178).
82. Tauer K, Fortner B, Zhu L, Ma L, Schwartzberg L. Final results of the national patient impact initiative. Abstract submitted to ASCO, 2005 (Abstract 8128).
83. Blakely J, Fortner B, Kulig K, Mao Q, Wagner S, Schwartzberg L. Patient-report symptom complaints associated with 5-FU + irinotecan (IRI) or oxaliplatin (OXALI) in colorectal cancer (CRC). Abstract submitted to ASCO, 2005 (Abstract 3649).
84. Fortner B, Tauer K, Ma L, Zhu O, Schwartzberg L. Final results of the national patient impact initiative. Abstract submitted at Oncology Nursing Society, 2005 (Abstract 719).
85. Lindsay B, Johnson G, Schwartzberg L, Fortner B. Methodological challenges and solutions for conducting quality of life research. Abstract submitted to Oncology Nursing Society, 2005 (Abstract 326).
86. Fortner B, Houts A, Johnson G, Schwartzberg L. A prospective investigation of chemotherapy-induced neutropenia (CIN) and quality of life (QoL). Abstract submitted at the 2005, 17th Multinational Association of Supportive Care in Cancer (MASCC) meeting (Abstract 25-183).
87. Fortner B, Ma L, Zhu L, Schwartzberg L. Status of anemia management in community oncology. Abstract submitted at the 2005, 17th Multinational Association of Supportive Care in Cancer (MASCC) meeting (Abstract 02-006).
88. Fortner B, Houts A, Johnson G, Schwartzberg L. Evaluation of the AIM Higher Initiative. Abstract submitted at the 2005, 17th Multinational Association of Supportive Care in Cancer (MASCC) meeting (Abstract 17-118).
89. Fortner B, Kulig K, Zhu L, Wagner S, Blakely J, Schwartzberg L. A patient-reported symptom complaints associated with 5FU + irinotecan (IRI) or oxaliplatin (OXALI) in colorectal cancer (CRC). Abstract submitted at the 2005, 17th Multinational Association of Supportive Care in Cancer (MASCC) meeting (Abstract 25-184).
90. Fortner B, Kulig K, Zhu L, Wagner S, Blakely J, Schwartzberg L. A patient-reported symptom complaints associated with 5FU + irinotecan (IRI) or oxaliplatin (OXALI) in colorectal cancer (CRC). Abstract submitted at the 2005 International Society of Gastrointestinal Oncology Meeting.
91. Fortner B, Tauer K, Okon T, Houts, Schwartzberg L. Experiencing neutropenia: Quality of life interviews with adult cancer patients. Abstract submitted to BMC Nursing (2005).
92. Fortner B, Zhu L, Tsong W, Burns C, Schwartzberg L. Patient burden, resource utilization, and treatment outcomes of grade 3/4 chimeric or humanized monoclonal antibody-associated infusion reactions. Abstract submitted to ASCO January 26-28 (2006).

93. Fortner B, Houts A, Johnson G, Schwartzberg L. A prospective Investigation of Chemotherapy Induced Neutropenia (CIN) and Quality of life (QoL). Abstract submitted to ASCO January 26-28 (2006).
94. Schwartzberg L, Cobb P, Henry D, Mintzer D, Epperson A, Fortner B. Phase II trial of nanoparticle albumin-bound paclitaxel (ABS) + capecitabine (XEL) in first line treatment of metastatic breast cancer (MBC). Abstracts submitted to ASCO January 26-28 (2006).
95. Ogle J, Fortner B, Moore K, Zhu L, Schwartzberg L. Human resource (HR) costs of chemotherapy infusion reactions (IR) in community oncology. Abstract submitted to ASCO January 26-28 (2006).
96. Houts A, Fortner B, Kaufman S, Miles K, Schwartzberg L. Item validation of Patient Care Monitor Version 2 (PCM2.0) using nurse interview and PCM1.0. Abstract submitted to ASCO January 26-28 (2006).
97. Blakely J, Schnell F, Kaywin P, Keaton M, Fortner B, Epperson A, Schwartzberg L. Phase II trial of Pemetrexed (P) and Gemcitabine (G) as first line chemotherapy for elderly and/or poor performance status patients with stage IIIB-IV non-small cell lung cancer (NSCLC). Abstract submitted to ASCO January 26-28 (2006).
98. Tauer K, Schwartzberg L, Epperson A, Fortner B. Randomized phase II trial of two different schedules of carboplatin (C) and paclitaxel (P) + trastuzumab (T) as first line treatment for metastatic breast cancer (MBC). Abstract submitted to ASCO January 26-28 (2006).
99. Tucker S, Binder S, Chau B, Houts A, Fortner B, Schwartzberg L. Zoledronic acid (ZA) to prevent bone loss during combined androgen blockade with finasteride (CAB+F) for clinically localized or recurrent non-osseous prostate cancer (PC). Abstract submitted to ASCO January 26-28 (2006).
100. Cobb P, Schwartzberg L, Kulig K, Johns A, Fortner B. Patterns of adjuvant hormonal therapy (AT) usage in early stage breast cancer (ESBC). Abstract submitted to ASCO January 26-28 (2006).
101. Blakely J, Schwartzberg L, Henry D, Sabbath K, Fu D, Epperson A, Fortner B. Randomized study of early intervention compared to standard intervention with darbepoetin-alpha (DA) for chemotherapy-induced anemia (CIA) in early stage breast cancer (ESBC). Abstract submitted to ASCO (2007).
102. Fortner B, Schwartzberg L, Stepanski E, Houts A, Fu D, Bibbs T. Human Resource (HR) Implications of IV Monoclonal Antibody (MoAb) Infusion Reactions (IR): Interim Data from a Time and Motion Study. Abstract published, Journal Supportive Oncology, Sept. 4(8);435 (2007).
103. Schwartzberg L, Hurwitz H, Stephenson J, Kotasek D, Goldstein D, Tebbut N, et al. Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC). Proc ASCO; X:A4081, 2007. (Presented)

104. Wielage R, Muehlenbein C, Liepa A, Babineaux S, Klein R, Schwartzberg L. The budgetary impact of Pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer (NSCLC). Poster presented at ISPOR 14th Annual International Mtg, Orlando, FL May (2009).
105. Girvan A, Peltz G, Pennella E, Pohl G, Faries D, Marciniak M, Obasaju C, Stepanski E, Schwartzberg L, Adjei A. An observational study of the impact of ethnicity on patients treated for non-small cell lung cancer (NSCLC) in the second-line setting with pemetrexed: Preliminary results in African Americans. Abstract submitted to ASCO May 29 - June 2 (2009). Published J Clin Oncol 27, 2009 (suppl; abstr e20624).
106. Houts A, Benn L, Lalla L, Solari P, Walker M, Stepanski E, Schwartzberg L. Test procedures and reasons why HER2-positive breast cancer patients did not receive trastuzumab in the adjuvant setting. Abstract submitted to ASCO June 4 – 8 (2010). Published J Clin Oncol 28, 2010 (suppl; abstr e11072).
107. Blakely L, Schwartzberg L, Wang G, Somer B, Wheeler M, Stepanski E, Walker M, Johns A. Phase II trial of combination therapy with metronomic capecitabine (C) and fulvestrant (F) in the treatment of hormone receptor-positive metastatic breast cancer (HR+ MBC). Abstract submitted to ASCO June 3 – 7 (2011). Published J Clin Oncol 29: 2011 (suppl; abstr e11087).
108. Pennella E, Pohl G, Girvan A, Winfree K, Martinez B, Obasaju C, Walker M, Stepanski E, Schwartzberg L, Adjei A. Prospective observational comparison of outcomes in African American and Caucasian patients receiving second-line treatment with pemetrexed for advanced non-small cell lung cancer (NSCLC). Abstract submitted to ASCO June 3 – 7 (2011). Published J Clin Oncol 29: 2011 (suppl; abstr e18008).
109. Stepanski E, Reyes C, Walker M, Satram-Hoang S, Leon L, Wojtowicz-Praga S, Miller P, Schwartzberg L. Association of skin rash severity and overall survival in patients receiving erlotinib for pancreatic cancer in the community setting. Abstract submitted to ASCO June 3 – 7 (2011). Published J Clin Oncol 29: 2011 (suppl; abstr e14508).
110. Walker M, Yu E, Kerr J, Yim Y, Stepanski E, Schwartzberg L. Self-reported symptom burden among patients receiving bevacizumab versus cetuximab containing regimens as second-line treatment of metastatic colorectal cancer. Abstract submitted to ASCO June 3 – 7 (2011). Published J Clin Oncol 29: 2011 (suppl; abstr e16598).

MANUSCRIPTS PUBLISHED IN PEER REVIEW JOURNALS

1. Liebowitz PJ, Schwartzberg LS, Bruce AK. The *In vivo* association of manganese with the chromosome of micrococcus radiodurans. Photochem Photobiol 23:45-50, 1976.
2. Braverman AS, Schwartzberg LS, Berkowitz R. Soluble and stroma-bound globulin chains in mild and severe B Thalassemia. Hemoglobin 6:347-367, 1982.
3. Huvos AG, Schwartzberg LS, Eds. Clinicopathologic Conference at Memorial Hospital: Fever and jaundice in a 22 year old woman with acute myelomonocytic leukemia. Cancer Invest 3:261-270, 1985.

CURRICULUM VITAE

Lee S. Schwartzberg, M.D.

Page 16

4. Huvos AG, Schwartzberg LS, Eds. Clinicopathologic Conference at Memorial Hospital: Hemolytic anemia, thrombocytopenia and renal failure in a patient apparently cured of anal carcinoma. *Cancer Invest* 3:481-489, 1985.
5. Kris MG, Schwartzberg LS, Gralla RJ: The role of chemotherapy in lung cancer. *Prim Care and Cancer* 6:15-21, 1986.
6. White DA, Schwartzberg LS, Kris MG, Bosl GJ: Acute chest pain syndrome during bleomycin infusions. *Cancer* 59:1582-1585, 1987.
7. Kris MG, Schwartzberg LS, Gralla RJ: Small cell lung cancer. *Prim Care and Cancer* 7:39-46, 1987.
8. Schwartzberg LS, Holbert JM. Hemorrhagic and thrombotic abnormalities of cancer. *Crit Care Clin* 4(1):107-28, 1988.
9. Marshall GD, Jr., Schwartzberg LS, Tauer KW, Lee P, Holbert JM, West WH: LAK cell therapy - clinical studies and future potential. *Prog Clin Biol Res* 337:555-8, 1990.
10. Schwartzberg LS, Birch R, Hazelton B, Tauer KW, Lee P, Altemose R, George C, Blanco R, Wittlin F, Cohen J, Muscato J, West WH: Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. *J Hematotherapy* 1:3167-327, 1992.
11. Bender JG To LB, Williams S, Schwartzberg LS: Defining a therapeutic dose of peripheral blood stem cells. *J Hematotherapy* 1:329-342, 1992.
12. Oldham RK, Blumenschein G, Schwartzberg LS, Birch R, and Arnold J: Combination biotherapy utilizing interleukin-2 and alpha Interferon in patients with advanced cancer: A National Biotherapy Study Group Trial. *Mol Biother*, 4 (3), March 1992.
13. Clark WC, Callihan T, Schwartzberg LS, Fontanesi J: Primary Intracranial Hodgkin's lymphoma without dural attachment: case report. - *J Neurosurgery* 76:692-5, 1992.
14. Schwartzberg L, Birch R, Blanco R, Wittlin F, Muscato J, Tauer K, Hazelton B, and West W: Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high dose chemotherapy. *Bone Marrow Transplant*. May, 11(5):369-374, 1993.
15. Dillman RO, Church C, Oldham RK, West WH, Barth NM, Schwartzberg LS, Arnold J, Birch R, Avent RA: Experience with high-dose continuous infusion interleukin-2 in the treatment of 788 cancer patients. *Cancer* 71(7):2358-2370, 1993.
16. Weaver C, Birch R, Schwartzberg L, Hazelton B, Palmer P, and West W. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients following the administration of myeloablative chemotherapy. *Blood*, Nov 15;86(10):3961-3969, 1995.

17. Ross AA, Loudovaris M, Hazelton B, Weaver CH, Schwartzberg L, and Bender JG. Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients. *Exp Hematol*, 23:1478-1483, 1995.
18. Weaver CH, Schwartzberg LS, Li W, Hazelton B, Palmer P, and West W. High dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease. *Bone Marrow Transplant*, 17:715-722, 1996.
19. Weaver CH, Hainsworth J, Greco FA, Schwartzberg L, Li W, Palmer P, Birch R, and West W. The treatment related mortality in 1,000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. *Bone Marrow Transplant*, 19:671-678, 1997.
20. Weaver CH, West WH, Schwartzberg LS, Birch R, McAneny B, Alberico T, Hainsworth J, Greco FA, Leff R, and Buckner CD. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. *Bone Marrow Transplant* 19:661-670, 1997.
21. Weaver CH, Potz J, Redmond J, Tauer KW, Schwartzberg LS, Kaywin P, Drapkin R, Grant B, Under P, Allen C, Longin K, Zhen B, Hazelton B, Buckner CD. Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ content. *Bone Marrow Transplant* 19(11):1103-1110, 1997.
22. Weaver CH, Schwartzberg LS, Zhen B, Mangum M, Leff R, Tauer K, Rosenberg A., Pendergrass K, Kaywin P, Hainsworth J, Greco FA, West WH, and Buckner CD. High-dose chemotherapy and peripheral blood stem cell infusion in patients with Non-Hodgkin's lymphoma: Results of outpatient treatment in community cancer centers. *Bone Marrow Transplant*, 20:753-760, 1997.
23. Weaver CH, Greco FA, Hainsworth J, Zhen B, Baldwin P, Wittlin F, Lewis M, Schwartzberg LS, and Buckner CD. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. *Bone Marrow Transplant*, 20:847-853, 1997.
24. Weaver CH, Schwartzberg LS, Birch R, Greco A, Hainsworth J, Drapkin R, Campos L, Grapski R, Schwerkoske J, Lautersztain J, Hazelton B, Schnell F, Babcock W, and Buckner CD. Collection of peripheral blood stem cells following the administration of paclitaxel, cyclophosphamide and filgrastim in patients with breast and ovarian cancer. *Biol Blood Marrow Transplant*, 3:83-90, 1997
25. Weaver CH, Schwartzberg LS, Birch R, Greco FA, Rhinehart S, Hainsworth J, Beeker T, Price H, Geier L, Foster J, West J, Hazelton B, and Buckner CD. Collection of peripheral blood progenitor cells following the administration of cyclophosphamide, etoposide and granulocyte-colony stimulating factor: an analysis of 497 patients. *Transfusion*, 37(9):896-903, 1997.
26. Weaver C, Birch R, Greco F, Schwartzberg L, McAneny B, Moore M, Oviatt D, Redmond J, George C, Alberico T, Buckner C. Mobilization and harvesting of peripheral blood stem cells: A randomized dose escalation trial of filgrastim. *Br J Haematol* 100:338-347, 1998

27. Weaver C, Schwartzberg L, Rhinehart S, West J, Zhen B, West W, Buckner C. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. *Bone Marrow Transplant* 21:383-389, 1998.
28. Weaver C, Moss T, Schwartzberg L, Zhen B, West J, Rhinehart S, Campos L, Beeker T, Lautersztain L, Buckner C. High-dose chemotherapy in patients with breast cancer: impact of infusing peripheral blood stem cells containing occult tumor cells. *Bone Marrow Transplant* 21:1117-1124, 1998.
29. Schwartzberg L, Weaver C, Birch R, Manner C, Tauer K, Beeker T., et al. A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II-III breast cancer. *J Hematother* 7:141-150,1998.
30. Weaver C, Schwartzberg L, Zhen B, Hazelton B, Weaver C, Tauer K, Raefsky E, Allen C, Longin K, Buckner C. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. *J Hematother* 7:241-249, 1998.
31. Weaver C, Zhen B, Schwartzberg L, Leff R, Magee M, Geier L, Deaton K, Lewkow L, Buckner C. Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. *Bone Marrow Transplant* 22:245-251, 1998.
32. Weaver C, Zhen B, Schwartzberg L, Walker C, Upton S, Buckner C. A randomized trial of mobilization of peripheral blood stem cells with cyclophosphamide, etoposide and G-CSF with or without cisplatin in patients with malignant lymphoma receiving high-dose chemotherapy. *Am J Clin Oncol* 21:408-412, 1998.
33. Schwartzberg L, Birch R, West W, Tauer K, Wittlin F, Leff R, Campos L, Rymer W, George C, Carter P, Mangum M, Greco F, Hainsworth J, Raefsky E, Blanco R, Buckner C, Weaver C. Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: Outpatient Administration in Community Cancer Centers. *Am J Clin Oncol*, 1998; 21(5):523-531.
34. Weaver C, West W, Schwartzberg L, Birch R, Buckner C. The rationale for performing autologous peripheral blood stem cell transplants in community cancer centers. *The Oncologist* 1998; 3(5):346-353.
35. Dillman R, Nayak S, Barth N, DeLeon C, Schwartzberg L, Spittler L, Church C, O'Connor A, Beutel L. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma. *Cancer Biotherapy Radiopharm.* 1998; Jun 13(3):165-176.
36. Weaver C, Schwartzberg L, Zhen B, Franco C, Moore M, Smith R, Jr., White L, Van Amburg A, Hazelton B, Buckner CD. Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m² of CY. *Bone Marrow Transplant.* 1999; Mar;23(5):421-5.

CURRICULUM VITAE

Lee S. Schwartzberg, M.D.

Page 19

37. Schwartzberg L, Birch R, Tauer K, Leff R, Greco F, Hainsworth J, Raefsky E, McAneny B, Weaver Z, West J, Buckner CD, Weaver CH. Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with five to nine involved axillary lymph nodes. *Am J Clin Oncol*. 1999 Apr;22(2):136-42.
38. Schwartzberg L, Weaver C, Campos L, Tauer K, Smith R, Zhen B, Birch R, Murphy M, Buckner C. High-Dose chemotherapy with peripheral blood stem cell support for operable locally advanced noninflammatory carcinoma of the breast. *Breast J*. 1999 Jul;5(4):238-245.
39. Schwartzberg L, Weaver C, Birch R, Giudice R, Sobong E, Schnell F, Kalman L, Buckner C. Single-agent paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy with peripheral blood stem cell support. *Am J Clin Oncol*. 1999 Apr;22(2):162-67.
40. Schwartzberg L, Weaver C, Lewkow L, McAneny B, Zhen B, Birch R, West W, Tauer K, Buckner C. High-dose chemotherapy with peripheral blood stem cell support for stage III-B inflammatory carcinoma of the breast. *Bone Marrow Transplant*. 1999 Nov;24(9):981-7.
41. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). *Pain*. 2001 Mar;91(1-2):123-30.
42. Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, Demetri G, Gordon D, Arseneau J, Savan A, Hynes H, Boccia R, O'Bryne J, Colowick AB. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. *Br J Cancer*. 2001 Apr;84 Suppl 1:17-23.
43. Dillman RO, DeLeon C, Beutel LD, Barth NM, Schwartzberg LS, Spitler LE, Garfield DH, O'Connor AA, Nayak SK. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma. *Crit Rev Oncol Hematol*. 2001 Jul-Aug;39(1-2): 115-23.
44. Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. *Crit Rev Oncol Hematol*. 2001 Oct;40(1):17-24.
45. Burgess J, Mills B, Griffith M, Mansour V, Weaver CH, Schwartzberg LS, Snyder EL, Krause DS, Yanovich S, Prilutskaya M, Umiel T, Moss TJ. Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34(+) cells. *Cytotherapy*. 2001;3(4)285-94.
46. Schwartzberg LS, Petak I, Stewart C, Turner PK, Ashley J, Tillman DM, Douglas L, Tan M, Billups C, Mihalik R, Weir A, Tauer K, Shope S, Houghton, JA. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. *Clin Cancer Res*. 2002 Aug;8(8):2488-98.
47. Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyan NS, Armstrong S, O'Byrne J, Rossi G, Colowick AB. Darbepoietin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. *Br J Cancer* 2002 Jul 29;87(3) 268-76.

48. Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, Jurcic J, Velez-Garcia E, Seiter K, Scheinberg D, Levitt D, Wedel N. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. *Leukemia*. 2003 Feb;17(2):314-8.
49. Fortner B, Okon T, Ashley J, Kepler G, Chavez J, Tauer K, Clements-Thompson M, Schwartzberg L, Demarco G, Houts AC. The Zero Acceptance of Pain (ZAP) Quality Improvement Project: evaluation of pain severity, pain interference, global quality of life, and pain-related costs. *J Pain Symptom Manage*. 2003 Apr;25(4):334-43.
50. Fortner B, Okon T, Schwartzberg L, Tauer K, Houts AC. The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. *J Pain Symptom Manage*. 2003 Dec;26(6):1077-92.
51. Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. *Clin Ther*. 2003 Nov;25(11):2781-96.
52. Turner PK, Houghton JA, Petak I, Tillman DM, Douglas L, Schwartzberg L, Billups CA, Panetta JC, Stewart CF. Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. *Cancer Chemother Pharmacol*. 2004 Mar;53(3):253-60.
53. Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. *Cancer*. 2004 Feb 15;100(4):859-68.
54. Turner PK, Houghton JA, Petak I, Tillman DM, Douglas L, Schwartzberg L, Billups CA, Panetta JC, Stewart CF. Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. *Cancer Chemother Pharmacol*. 2004 Mar;53(3):253-60.
55. Fortner BV, Tauer K, Zhu L, Okon TA, Moore K, Templeton D, Schwartzberg L. Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities. *BMC Cancer*. 2004 May 20;4(1):22.
56. Fortner B, Okon T, Zhu L, Tauer K, Moore K, Templeton D, Schwartzberg L. Costs of human resources in delivering cancer chemotherapy and managing chemotherapy-induced neutropenia in community practice. *Community Oncology*, 2004 Vol.1(1)23-28.
57. Fortner B, Tauer K, Zhu L, Ma L, Schwartzberg L. The impact of medical visits for chemotherapy-induced anemia and neutropenia on the patient and caregiver. *Community Oncology*, 2004 Vol.1(4)211-216.
58. Vogel C, Wojtukiewicz M, Carroll R, Tjulandin S, Barajas-Figueroa L, Wiens B, Neumann T, Schwartzberg L. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. *J Clin Oncol*. 2005 Feb 20;23(6):1178-84.

59. Fortner B, Schwartzberg L, Tauer K, Houts A, Hackett J, Stolshek B. Impact of chemotherapy-induced neutropenia on quality of life: a prospect pilot investigation. *Journal of Supportive Care in Cancer*, 2005. Vol.13 (7)522-528.
60. Baldwin S, Schwartzberg L, Houts A, Fortner B. Validation of the cancer care monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. *Journal of Pain and Symptom Management*, 2005. Vol.31(3), 207-214.
61. Fortner B, Okon T, Schwartzberg L, Tauer K, Houts A. Experiencing Neutropenia: Quality of Life interviews with adult cancer patients. *BMC Nursing*, 2005. 4(4), doi:10.1186/1472-6955-4-4.
62. Schwartzberg L, Fortner B, Houts A. Sex differences in patients who have cancer with mild anemia: symptom burden and quality of life. *Supportive Cancer Therapy*, 2005. Jul 1;2(4), 241-6.
63. Schwartzberg L. Erythropoietic therapy: who, how, and when? *Support Cancer Ther*. 2006. Jan 1;3(2):125-6.
64. Schwartzberg L. Neutropenia: etiology and pathogenesis. *Clin Cornerstone*. 2006;8 Suppl 5:S5-11. Review.
65. Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. *J Support Oncol*. 2006 Feb;4(2 Suppl 1):3-8.
66. Fortner B, Schwartzberg L, Stepanski E, Houts A, Fu D, Bibbs T. Human resource (HR) implications of IV monoclonal antibody (MoAb) infusion reactions (IR): Interim data from a time and motion study [abstract]. *Journal Supportive Oncology* 2006. Vol. 4(8).
67. Fortner B, Baldwin S, Schwartzberg L, Houts AC. Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. *J Pain Symptom Manage*. 2006 Mar;31(3):207-14.
68. Elting L, Fortner B, Bosserman L, House A, Schwartzberg L. If at first you don't succeed, don't quit, try again: The Centers for Medicare and Medicaid Services demonstration project on quality of care-2006 and 2006. *J Support Oncol*. 2006 Mar;4(3):147-51.
69. Nordyke R, Chang C, Chiou C, Wallace J, Yao B, Schwartzberg L. Validation of a patient satisfaction questionnaire for anemia treatment, the PSQ-An. *Health Qual Life Outcomes* 2006. May 3;4:28.
70. Smith T, Khatcheressian J, Lyman G, Schwartzberg L et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. *J Clin Oncol*. 2006 Jul 1;24(19):3187-205.
71. Fortner B, Houts A, Schwartzberg L. A prospective investigation of chemotherapy-induced neutropenia and quality of life. *J Supportive Oncol* 2006 Oct; 14(9):472-8.

72. Govindan R, Crowley J, Schwartzberg L et al. Phase II trial of bexarotene capsules in patients with advanced non-small cell lung cancer after failure of two or more previous therapies. *J Clin Oncol*. 2006 Oct 20;24(30):4848-54.
73. Schwartzberg L, Fortner B, Houts A. American Society of Clinical Oncology 2007 Educational book. R. Govindan, MD (Eds.), Use of Technology to Enhance Doctor-Patient Interactions. (pp. 686-691). Chicago, Illinois.
74. Dillman R, DePriest C, DeLeon C, Barth N, Schwartzberg L, et al. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma. *Cancer Biotherapy and Radiopharmaceuticals* 2007 Jun;22(3):309-21.
75. Schwartzberg L. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? *Oncology (Williston Park)*. 2007 Jul;21(8):946-53; discussion 954, 959, 962 passim. Review.
76. Fortner B, Schwartzberg L, Stepanski E, Houts A. Symptom burden for patients with metastatic colorectal cancer treated with first-line FOLFOX or FOLFIRI with and without bevacizumab in the community setting. *Support Cancer Ther*. 2007 Sep 1;4(4):233-40.
77. Schwartzberg L, Stepanski E, Fortner B, Houts A. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. *Support Care Cancer*. 2008 Apr;16(4):393-8.
78. Mauer A, Cohen E, Ma P, Kozloff M, Schwartzberg L, et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. *J Thorac Oncol*. 2008 Jun;3(6):631-6.
79. Bunnell C, Vahdat L, Schwartzberg L, Gralow J, Klimovsky J, Poulart V, et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. *Clin Breast Cancer*. 2008 Jun;8(3):234-41.
80. Hochster H, Hart L, Ramanathan R, Childs B, Schwartzberg L, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. *J Clin Oncol*. 2008 Jul 20;26(21):3523-9.
81. Robinson K, Williams M, van der Jagt R, Schwartzberg L, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and Mantle cell non-Hodgkin's lymphoma. *J Clin Oncol* 2008. Sept 20;26(27):4473-9.
82. Schwartzberg L, Stepanski E, Walker M, Mathias S, Houts A, Fortner B. Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. *Support Care Cancer* 2009. Jan;17(1):91-8.
83. Fields A, Keller A, Schwartzberg L, Bernard S, Kardinal C, Cohen A., et al. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. *J Clin Oncol* 2009. April 20;27(12):1941-7.

84. Schwartzberg L, Cobb P, Senecal F, Henry D, Kulig K, Walker M, et al. Initial treatment and changes in adjuvant endocrine therapy of early stage breast cancer. *Breast* 2009. April; 18(2): 78-83.
85. Stepanski E, Walker M, Schwartzberg L, Blakely L, Ong J, Houts A. The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer. *J Clin Sleep Med*. 2009. April 15;5(2): 132-6.
86. Walker M, Schwartzberg L, Stepanski E, Fortner, B. A retrospective study of quality of life in a community sample of patients with early stage breast cancer. *Breast Cancer Res Treat* 2009. May;115(2):415-22.
87. Jain A, Hughes R, Sandler A, Dowlati A, Schwartzberg L, Dobbs T, et al. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). *J Thorac Oncol* 2009. Jun;4(6):722-7.
88. Blackwell K, Pegram M, Tan-Chiu E, Schwartzberg L, Arbushites M, Maltzman J, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first-or second-line trastuzumab-containing regimens. *Ann Oncol* 2009. Jun;20(6):1026-31.
89. Schwartzberg L, Cobb P, Walker M, Stepanski E, Houts A. Patient and practice impact of capecitabine compared to Taxanes in first-/second-line chemotherapy for metastatic breast cancer. *Support Care Cancer* 2009. Aug;17(8):1081-1088.
90. Blakely L, Schwartzberg L, Keaton M, Schnell F, Henry D, Epperson A, Walker M. A Phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB-IV non-small cell lung cancer. *Lung Cancer* 2009. Oct;66(1):97-102.
91. Stepanski E, Houts A, Schwartzberg L, Walker M, Reyes C, Blakely J. Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden. *Clin Lung Cancer* 2009 Nov;10(6):426-32.
92. Klein R, Muehlenbein C, Liepa A, Babineaux S, Wielage R, Schwartzberg L. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. *J Thorac Oncol* 2009 Nov;4(11):1404-14.
93. Schwartzberg L, Franco S, Florance A, O'Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. *Oncologist* 2010; Feb15(2):122-9.
94. Burris H, Belani C, Kaufman P, Gordon A, Schwartzberg L, Paroly W., et al. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin's lymphoma: results of four multicenter, double-blind randomized phase II studies. *J Oncol Pract* 2010. May; 6(3):133-140.

95. Klein R, Wielage R, Muehlenbein C, Liepa A, Babineaux S, Lawson, A, Schwartzberg L. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. *J Thorac Oncol* 2010. Aug;5(8):1263-72.
96. Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, et al. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial. *BMC Cancer* 2010. Oct 25;10:581.
97. Dunn J, Ellis P, fox J, Klein I, Lopes M, Nash D, Nishida L, Schwartzberg L, Wong W. Payer and provider collaborations that improve quality outcomes in oncology. *Manag Care* 2010. Nov;19(11):35-40, 42.
98. Kris M, Urba S, Schwartzberg L. Clinical roundtable monograph. Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion. *Clin Adv Hematol Oncol* 2011. Jan;9(1):suppl 1-15.
99. Schwartzberg L, Szabo S, Giolmore J, Haislip S, Jackson J, Jain G., et al. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC). *Curr Med Res Opin* 2011. Apr;7(4):837-45.
100. Streeter S, Schwartzberg L, Husain N, Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. *J Oncol Pract* 2011. May; 7(3S);46s-51s.
101. Okon T, Schwartzberg L. Are we winning the war on Cancer? *J Oncol Pract* 2011. May;7(3S); 62s-64s.
102. Walker M, Hasan M, Yim Y, Yu E, Stepanski E, Schwartzberg L. Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients. *Health Qual Life Outcomes* 2011. Jun 20;9:46
103. Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting. *Expert Rev Pharmacoecon Outcomes Res* 2011. Aug;11(4):481-8.
104. Schwartzberg L, Morrow G, Balu S, Craver C, Gayle J, Cox D. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States. *Curr Med Res Opin* 2011. Aug;27(8):1613-22.
105. Walker MS, Stepanski EJ, Reyes C, Satram-Hoang S, Houts AC, Schwartzberg LS. Symptom burden and quality of Life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation. *Therapeutic Advances in Hematology* 2011;2(3):129-139.
106. Schwartzberg LS, Grunberg SM, Kris MG. Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting. *Clin Adv Hematol Oncol*. 2011 Nov;9(11 Suppl 27):1-14.

107. Okon T, Schwartzberg L. Are we winning the war on Cancer? *Am J Manag Care* 2012.Feb;18 (1 Spec No.)
108. Schwartzberg LS, Arena F, Mintzer D, Epperson A, Walker MS. Phase II, multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer. *Clinical Breast Cancer* 2012. Apr;12(2):87-93.
109. Stepanski EJ, Reyes C, Walker MS, Hoang SS, Leon L, Wojtowicz-Praga S, Miller PJE, Houts AC, Schwartzberg LS. The association of skin rash severity with overall survival: Findings from patients receiving erlotinib for pancreatic cancer in the community setting. *Pancreas* 2012. June 13.
110. Walker MS, Yu E, Kerr J, Yim YM, Stepanski EJ, Schwartzberg LS. Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer: a retrospective review. *BMC Res Notes* 2012. Jun 20;5(1):314.
111. Buzdar A, Vogel C, Schwartzberg L, Garin A, Perez A, Ingle J., et al. Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer. *Cancer*. 2012 Jul 1;118(13):3244-53.
112. Schwartzberg L, Jacobs P, Matsouka P, Azevedo W, Pinto A. the role of second-generation 5-HT(3) receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies. *Crit Rev Oncol Hematol*. 2012 Jul;83(1):59-70.
113. Walker MS, Pharm EY, Kerr J, Yim YM, Stepanski EJ, Schwartzberg LS. Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer. *BMC Res Notes*. 2012 Jun 20;5:314.
114. Schwartzberg LS, Jacobs P, Matsouka P, Azevedo W, Pinto A. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies. *Crit Rev Oncol Hematol*. 2012 Jul;83(1)59-70.
115. Buzdar A, Vogel C, Schwartzberg L, Garin A, Perez A, Ingle J, Houghton M., et al. Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer. *Cancer* 2012 Jul 1;118(13):3244-53.
116. Gradishar WJ, Kaklamani V, Sahjoo TP, Lokanatha D, Raina V, Bondarde S, Jain M, Ro SK, Lokker NA, Schwartzberg L. A double-blind, randomized, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. *Eur J Cancer* 2013 Jan; 49(2):312-22.
117. Stepanski EJ, Reyes C, Walker MS, Satram-Hoang S, Leon L, Wojtowicz-Praga S, Miller PJ, Houts AC, Schwartzberg LS. The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. *Pancreas*. 2013 Jan;42(1):32-6.
118. Tillmanns TD, Lowe MP, Walker MS, Stepanski EJ, Schwartzberg LS. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. *Gynecol Oncol*. 2013 Feb;128(2):221-8.

119. Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT., et al. Sorafenib with gemcitabine or capecitabine in patients with HER-2 negative advanced breast cancer that progressed during or after bevacizumab. *Clin Cancer Res.* 2013 May 15;19(10):2745-54.
120. Ramsey SD, Sullivan SD, Reed SD, Tina Shih YC, Schaecher K, Dhanda R, Patt D, Pendergrass K, Walker M, Malin J, Schwartzberg L, Neumann K, Yu E, Ravelo A, Small A. Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting. *Oncologist.* 2013 Jun;18(6):760-7
121. Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS et al. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. National Comprehensive Cancer Network. *J Natl Compr Canc Netw.* 2013 Jul;11(7):753-60.
122. Baselga J, Costa F, Gomez H, Hudis CA, Rapoport B, Roche H, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ. A phase 3 trial comparing capecitabine in combination with Sorafenib or placebo for treatment of locally advanced or metastatic HER2-Negative breast Cancer (the RESILIENCE study): study protocol for a randomized controlled trial. *Trials.* 2013 Jul 22;14:228.
123. Wan Y, Gao X, Mehta S, Wang Z, Faria C, Schwartzberg L. Indirect costs associated with metastatic breast cancer. *J Med Econ.* 2013 Oct;16(10):1169-78.
124. Choy H, Schwartzberg LS, Dakhil SR, Garon EB, Gerber DE, Choksi JK, et al. Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. *J Thorac Oncol.* 2013 Oct;8(10):1308-16.
125. Miller PJ, Balu S, Buchner D, Walker MS, Stepanski EJ, Schwartzberg LS. Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer. *J Med Econ.* 2013 Oct;16(10):1179-89.
126. Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahan B, Rugo HS, Saad AA, Schwartzberg LS, et al. Myeloid growth factors. *J Natl Compr Canc Netw.* 2013 Oct 1;11(10):1266-90.

127. Pennella E, Obasaju CK, Pohl G, Peltz G, Girvan AC, Winfree KB, Martinez B, Marciniak M, Walker MS, Stepanski E, Schwartzberg LS, Adjei A. Prospective observational comparison of clinical outcomes between african-american and caucasian patients receiving second-line treatment with pemetrexed for advanced non-small-cell lung cancer. *Clin Lung Cancer*. 2013 Nov;14(6):726-35.
128. Fuchs CS, Fakih M, Schwartzberg L, Cohn AL, Yee L, Dreisbach L, et al. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. *Cancer*. 2013 Dec 15;119(24):4290-8.
129. Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. *Lancet Oncol*. 2013 Dec; 14(13):1326-36.
130. Schwartzberg LS, Wang G, Somer BG, Blakely LJ, Wheeler BM, Walker MS, et al. Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. *Clin Breast Cancer*. 2014 Feb;14(1):13-9.
131. Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD, Cox D. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). *Support Care Cancer*. 2014 Feb;22(2):469-77.
132. Stewart CF, Tagen M, Schwartzberg LS, Blakely LJ, Tauer KW, Smiley LM. Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors. *Cancer Chemother Pharmacol*. 2014 Mar;73(3):561-8.
133. Schwartzberg L, Hermann R, Flinn I, Flora D, Hsi ED, Hamid O, Shi P, Lin BK, Myrand SP, Nguyen TS, Dreyling M. Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma. *Br J Haematol*. 2014 Mar 27.
134. Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, et al. Breast cancer version 3.2014. *J Natl Compr Canc Netw*. 2014 Apr;12(4):542-90.
135. McIntyre K, O'Shaughnessy J, Schwartzberg L, Glück S, Berrak E, Song JX, Cox D, Vahdat LT. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. *Breast Cancer Res Treat*. 2014 Apr 4.

136. Simon SM, Schwartzberg LS. A review of rapid-onset opioids for breakthrough pain in patients with cancer. *J Opioid Manag.* 2014 May-Jun;10(3):207-15.
137. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY. PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. *J Clin Oncol.* 2014 Jul 20;32(21):2240-7.
138. Walker MS, Masaquel AS, Kerr J, Lalla D, Abidoeye O, Houts AC, Schwartzberg LS. Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient-reported symptom burden. *Breast Cancer Res Treat.* 2014 Apr;144(3):673-81.
139. Schwartzberg LS, Badarinath S, Keaton MR, Childs BH. Phase II Multicenter Study of Docetaxel and Bevacizumab With or Without Trastuzumab as First-Line Treatment for Patients With Metastatic Breast Cancer. *Clin Breast Cancer.* 2014 Jun;14(3):161-8.
140. Schwartzberg L, Hermann R, Flinn I, Flora D, His ED, Hamid O, et al. Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma. *Br J Haematol.* 2014 Jul;166(1):91-7.
141. McIntyre K, O'Shaughnessy J, Schwartzberg L, Gluckl S, Berrak E, Song J et al. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. *Breast Cancer Res Treat.* 2014 Jul;146(2):321-8.
142. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. *J Clin Oncol.* 2014 Jul 20;32(21):2240-7.
143. Schwartzberg LS, Saleh M, Whittaker S, Abella E. Severe neutropenia and relative dose intensity among patients <65 and ≥65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapy. *Support Care Cancer.* Jul;22(7):1833-41.
144. Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. *Ann Oncol.* 2014 Jul;25(7):1328-33.

145. Barnes G, Pathak A, Schwartzberg L. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review. *Adv Ther.* 2014 Jul;31(7):683-95.
146. O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. *J Clin Oncol.* 2014 Dec 1;32(34):3840-7.
147. Barnes G, Pathak A, Schwartzberg L. G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. *Cancer Med.* 2014 Dec;3(6):1477-84.
148. Schwartzberg L Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting. *Expert Rev Pharmacoecon Outcomes Res.* 2014 Dec;14(6):825-34.
149. Wilks S, Puhalla S, O'Shaughnessy J, Schwartzberg L, Berrak E, Song J, et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. *Clin Breast Cancer.* 2014 Dec;14(6):405-12.
150. Yardley DA, Kaufman PA, Huang W, Krekow L, Savin M, Lawler WE, Zrada S, Starr A, Einhorn H, Schwartzberg LS, et al. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival. *Breast Cancer Res.* 2015 Mar 18;17:41.
151. Schwartzberg LS, Rugo HS, Apro MS. New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting. *Clin Adv Hematol Oncol.* 2015 Mar;13(3 Suppl 3):3-13.
152. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, et al. Breast Cancer Version 2.2015. *J Natl Compr Canc Netw.* 2015 Apr;13(4):448-75.
153. Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, et al. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. *J Clin Oncol.* 2015 May 10;33(14):1574-83.
154. Tebbutt N, Kotasek D, Burris HA, Schwartzberg LS, Hurwitz H, Stephenson J, Warner DJ, Chen L, Hsu CP, Goldstein D. Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. *Cancer Chemother Pharmacol.* 2015 May; 75(5):993-1004.

155. Dillman RO, McClay EF, Barth NM, Amatruda TT, Schwartzberg LS, Mahdavi K, de Leon C, Ellis RE, DePriest C. Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. *Cancer Biother Radiopharm.* 2015 Jun;30(5):187-94.
156. Schwartzberg L, Harrow B, Lal LS, Radtchenko J, Lyman GH. Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens. *Am Health Drug Benefits.* 2015 Jul-Aug;8(5):273-82.
157. Graham CN, Hechmati G, Fakhri MG, Knox HN, Maglinte GA, Hjelmgren J, Barber B, Schwartzberg LS. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. *J Med Econ.* 2015 Aug;18(8):619-28.
158. Hesketh PJ, Aapro M, Jordan K, Schwartzberg L, Bosnjak S, Rugo H. A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting. *Biomed Res Int.* 2015;2015:651879. Sep 3. Review.
159. Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. *Cancer Treat Rev.* 2015 Sep;41(8):653-9.
160. Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig ID. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. *Lancet Oncol.* 2015 Sep;16(9):1071-8.
161. Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. *Lancet Oncol.* 2015 Sep;16(9):1079-89.
162. O'Shaughnessy J, McIntyre K, Schwartzberg L, Wilks S, Puhalla S, Berrak E, Song J, Vahdat L. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies. *Springerplus* 2015 Sep 21;4:532.

163. Roeland E, Schwartzberg LS, Aapro MS. Q&A. *Clin Adv Hematol Oncol*. 2015 Oct;13(10 Suppl 10):12-3.
164. Schwartzberg LS. Best Use of Guidelines for the Management of Chemotherapy-Induced Nausea and Vomiting. *Clin Adv Hematol Oncol*. 2015 Oct;13(10 Suppl 10):9-11.
165. Perez EA, Awada A, O'Shaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J. Etrinecetan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol*. 2015 Nov;16(15):1556-68.
166. Bond TC, Mueller U, Barnes G, Gennero R, Tang B, Schwartzberg L. Lipegfilgrastim For Reduction Of Chemotherapy-Induced Neutropenia Related Events: A Meta-Analysis. *Value Health*. 2015 Nov;18(7):A434.
167. Lyman GH, Lal L, Radtchenko J, Harrow B, Schwartzberg L. Evaluation Of Resource Utilization For Chemotherapy Induced Nausea And Vomiting (Cinv) In Patients Treated With Anthracycline+Cyclophosphamide (Ac) For Solid Cancers With And Without Nk-1 Based Regimens. *Value Health*. 2015 Nov;18(7):A465.
168. Gatwood J, Graetz I, Stepanski E, Vidal G, Schwartzberg L. Prevalence And Reasons For Nonadherence To Aromatase Inhibitors In An Outpatient Oncology Clinic. *Value Health*. 2015 Nov;18(7):A467.
169. Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE 3rd, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ Jr, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM. NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. *J Natl Compr Canc Netw*. 2015 Nov;13(11):1337-46.
170. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Sheard DA, Kumar R. Breast Cancer, Version 1.2016. *J Natl Compr Canc Netw*. 2015 Dec;13(12):1475-85.

171. Schwartzberg LS. 15 years of The Lancet Oncology. *Lancet Oncol.* 2015 Dec;16(16):1588-91.
172. Walker MS, Pohl GM, Houts AC, Peltz G, Miller PJ, Schwartzberg LS, Stepanski EJ, Marciniak M. Analysis of the psychological impact of cancer-related symptoms on patients with non-small cell lung cancer. *Psychooncology.* 2016 Jan 20.
173. Rapoport B, Schwartzberg L, Chasen M, Powers D, Arora S, Navari R, Schnadig I. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. *Eur J Cancer.* 2016 Apr;57:23-30.
174. Schwartzberg L. Progress in chemoradiotherapy-induced nausea and vomiting. *Lancet Oncol.* 2016 Mar 4. S1470-2045(16)00034-6.
175. Schwartzberg LS, Rugo HS, Aapro MS. New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting. *Clin Adv Hematol Oncol.* 2015 Mar;13(3 Suppl 3):3-13.
176. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2016 Mar;14(3):324-54.
177. Schnadig ID, Agajanian R, Dakhil C, Gabrail NY, Smith RE Jr, Taylor C, Wilks ST, Schwartzberg LS, Cooper W, Mosier MC, Payne JY, Klepper MJ, Vacirca JL. APF530 (Granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. *Future Oncol.* 2016 Mar 21.
178. Yardley DA, Kaufman PA, Huang W, Krekow L, Savin M, Lawler WE, Zrada S, Starr A, Einhorn H, Schwartzberg LS, Adams JW, Lie Y, Paquet AC, Sperinde J, Haddad M, Anderson S, Brigino M, Pesano R, Bates MP, Weidler J, Bosserman L. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival. *Breast Cancer Res.* 2015 Mar 18;17:41.
179. Strauss WM, Carter C, Simmons J, Klem E, Goodman N, Vahidi B, Romero J, Masterman-Smith M, O'Regan R, Gogineni K, Schwartzberg L, Austin LK, Dempsey PW, Cristofanilli M. Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers. *Oncotarget.* 2016 Mar 30.

180. Graham CN, Maglinte GA, Schwartzberg LS, Price TJ, Knox HN, Hechmati G, Hjelmgren J, Barber B, Fakih MG. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-Type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. *Clin Ther*. 2016 Apr 13. S0149-2918(16)30160-6.
181. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, et al. Breast Cancer Version 2.2015. *J Natl Compr Canc Netw*. 2015 Apr;13(4):448-75.
182. Tebbutt N, Kotasek D, Burris HA, Schwartzberg LS, Hurwitz H, Stephenson J, Warner DJ, Chen L, Hsu CP, Goldstein D. Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. *Cancer Chemother Pharmacol*. 2015 May;75(5):993-1004.
183. Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, et al. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. *J Clin Oncol*. 2015 May 10;33(14):1574-83.
184. Dillman RO, McClay EF, Barth NM, Amatruda TT, Schwartzberg LS, Mahdavi K, de Leon C, Ellis RE, DePriest C. Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. *Cancer Biother Radiopharm*. 2015 Jun;30(5):187-94.
185. Schwartzberg L, Harrow B, Lal LS, Radtchenko J, Lyman GH. Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens. *Am Health Drug Benefits*. 2015 Jul-Aug;8(5):273-82.
186. Graham CN, Hechmati G, Fakih MG, Knox HN, Maglinte GA, Hjelmgren J, Barber B, Schwartzberg LS. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. *J Med Econ*. 2015 Aug;18(8):619-28.
187. Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. *Cancer Treat Rev*. 2015 Sep;41(8):653-9.

188. Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig ID. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. *Lancet Oncol.* 2015 Sep;16(9):1071-8.
189. Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. *Lancet Oncol.* 2015 Sep;16(9):1079-89.
190. O'Shaughnessy J, McIntyre K, Schwartzberg L, Wilks S, Puhalla S, Berrak E, Song J, Vahdat L. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies. *Springerplus.* 2015 Sep 21;4:532.
191. Hesketh PJ, Aapro M, Jordan K, Schwartzberg L, Bosnjak S, Rugo H. A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting. *Biomed Res Int.* 2015; 2015:651879.
192. Schwartzberg LS. Best Use of Guidelines for the Management of Chemotherapy-Induced Nausea and Vomiting. *Clin Adv Hematol Oncol.* 2015 Oct;13(10 Suppl 10):9-11.
193. Roeland E, Schwartzberg LS, Aapro MS. Q&A. *Clin Adv Hematol Oncol.* 2015 Oct;13(10 Suppl 10):12-3.
194. Perez EA, Awada A, O'Shaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol.* 2015 Nov;16(15):1556-6.
195. Gatwood J, Graetz I, Stepanski E, Vidal G, Schwartzberg L. Prevalence And Reasons For Nonadherence To Aromatase Inhibitors In An Outpatient Oncology Clinic. *Value Health.* 2015 Nov;18(7):A467.

196. Lyman GH, Lal L, Radtchenko J, Harrow B, Schwartzberg L. Evaluation Of Resource Utilization For Chemotherapy Induced Nausea And Vomiting (Cinv) In Patients Treated With Anthracycline+Cyclophosphamide (Ac) For Solid Cancers With And Without Nk-1 Based Regimens. *Value Health*. 2015 Nov;18(7):A465.
197. Bond TC, Mueller U, Barnes G, Gennero R, Tang B, Schwartzberg L. Lipegfilgrastim For Reduction Of Chemotherapy-Induced Neutropenia Related Events: A Meta-Analysis. *Value Health*. 2015 Nov;18(7):A434.
198. Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE 3rd, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ Jr, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM. NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. *J Natl Compr Canc Netw*. 2015 Nov;13(11):1337-46.
199. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shad DA, Kumar R. Breast Cancer, Version 1.2016. *J Natl Compr Canc Netw*. 2015 Dec;13(12):1475-85.
200. Schwartzberg LS. 15 years of The Lancet Oncology. *Lancet Oncol*. 2015 Dec;16(16):1588-91.
201. Walker MS, Pohl GM, Houts AC, Peltz G, Miller PJ, Schwartzberg LS, Stepanski EJ, Marciniak M. Analysis of the psychological impact of cancer-related symptoms on patients with non-small cell lung cancer. *Psychooncology*. 2016 Jan 20.
202. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shad DA, Kumar R. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2016 Mar;14(3):324-54.
203. Schnadig ID, Agajanian R, Dakhil C, Gabrail NY, Smith RE Jr, Taylor C, Wilks ST, Schwartzberg LS, Cooper W, Mosier MC, Payne JY, Klepper MJ, Vacirca JL. APF530 (Granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. *Future Oncol*. 2016 Mar 21.

204. Strauss WM, Carter C, Simmons J, Klem E, Goodman N, Vahidi B, Romero J, Masterman-Smith M, O'Regan R, Gogineni K, Schwartzberg L, Austin LK, Dempsey PW, Cristofanilli M. Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers. *Oncotarget*. 2016 Mar 30.
205. Schwartzberg L. Progress in chemoradiotherapy-induced nausea and vomiting. *Lancet Oncol*. 2016 Mar 4. pii: S1470-2045(16)00034-6.
206. Rapoport B, Schwartzberg L, Chasen M, Powers D, Arora S, Navari R, Schnadig I. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. *Eur J Cancer*. 2016 Apr;57:23-30.
207. Graham CN, Maglinte GA, Schwartzberg LS, Price TJ, Knox HN, Hechmati G, Hjelmgren J, Barber B, Fakih MG. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-Type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. *Clin Ther*. 2016 Apr 13. pii: S0149-2918(16)30160-6.

POSTERS

1. Tauer K, Schwartzberg L, Ashley J, Fleagal J, Keppler G, Coluzzi P, Chavez J, Fortner B, Glajchen M, Portenoy R. Implementing a practical, structured approach to cancer pain management in outpatient oncology practice. Poster presented to the Annual Meeting of the American Pain Society, San Diego, CA, 1998.
2. Houts A, Fortner B, Tauer K, Weir A, Wheeler B, Schwartzberg L, Okon T. Reliability and validity of the cancer care monitor. Poster presented at the 38th Annual Meeting of American Society of Clinical Oncology, Orlando, FL, 2002.
3. Fortner B, Stolshek B, Tauer K, Okon T, Durrence H, White J, Houts A, Schwartzberg L. Chemotherapy induced neutropenia is associated with lower quality of life in patients with cancer. Poster presented at 27th Annual ESMO Congress, Nice, France, 2002.
4. Fortner B, Durrence H, Mao Q, Schwartzberg L, Houts A. Development, reliability, and validity of the Cancer Care Monitor Neutropenia Index (CCM-N). Poster session presented at ASH Convention, Philadelphia, PA, 2002.
5. Fortner B, Stolshek B, Tauer K, Okon T, Durrence H, White J, Houts A, Schwartzberg L. Chemotherapy-induced neutropenia (CIN) is associated with lower quality of life in patients with cancer. Poster presented at the European Cancer Conference, Copenhagen, Denmark, 2003.

6. Fortner B, Durrence H, Houts A, Schwartzberg L. Validation of the functional assessment of cancer therapy-neutropenia (FACT-N) and the Cancer Care Monitor-Neutropenia Index (CCM-N). Poster presented at ASH Convention, San Diego, CA, 2003.
7. Schwartzberg L, Yee L, Senecal F, Charu V, Yao B, Mendes E, Rossi G. Early results of a head to head comparison of darbepoetin alfa 200 MCG given every 2 weeks (Q2W) and epoetin alfa 40,000 U given weekly (QW). Poster presented at ASH Convention, San Diego, CA, 2003.
8. Fortner B, Tomita D, Stolshek B, Schwartzberg L. Dosing patterns and clinical outcomes of erythropoietic agents for the treatment of anemia in patients with nonmyeloid malignancies receiving chemotherapy. Poster presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, 2003.
9. Fortner B, Mao Q, Stolshek B, Schwartzberg L. Association of IV antibiotic use and hospitalization with filgrastim (F) and pegfilgrastim (PEGF) utilization in a community oncology clinic sample. Poster presented at ASHP Convention, New Orleans, LA, 2003.
10. Fortner B, Mao Q, Stolshek B, Schwartzberg L. Association of IV antibiotic use and hospitalization with filgrastim (F) and pegfilgrastim (PEGF) utilization in a community oncology clinic sample. Poster presented at Mechanisms and Treatment of Cancer-Related Symptoms: Basic Science Colloquium, Houston, TX 2004.
11. Fortner B, Zhu L, Tauer K, Schwartzberg L. The impact of anemia treatment visits on the patient and their caregiver. Poster presented at 40th Annual ASCO meeting, New Orleans, LA, 2004.
12. Fortner B, Okon T, Zhu , Tauer K, Moore K, Templeton D, Schwartzberg L. Human resource costs and patient time affected by the delivery of chemotherapy and neutropenia management. Poster presented at 40th Annual ASCO meeting, New Orleans, LA, 2004.
13. Fortner B, Miles K, Zhu L, Schwartzberg L. The development of a community oncology human resource (HR) cost model for chemotherapy-induced anemia (CIA). Poster presented at 16th MASCC International Symposium, Miami, FL, 2004.
14. Fortner B, Moore K, Tauer K, Templeton D, Okon T, Johnson G, Schwartzberg L. Baseline evaluation of the AIM Higher Initiative: patient interview data. Poster presented at 16th MASCC International Symposium, Miami, FL, 2004.
15. Fortner B, Lipinski D, Baldwin S, Schwartzberg L, Houts A. Utility of the cancer care monitor to identify depression and anxiety in community oncology. Poster presented at 16th MASCC International Symposium, Miami, FL, 2004.
16. Schwartzberg L, Zhu L, Tauer K, Fortner B. The impact of anemia treatment visits on the patient and their caregiver. Poster presented at 16th MASCC International Symposium, Miami, FL, 2004.
17. Schwartzberg L, Fortner B, Houts A. Symptom burden and quality of life differs by gender in cancer patients with mild anemia. Poster presented at 16th MASCC International Symposium, Miami, FL, 2004.

18. Schwartzberg L, Tauer K, Fortner B, Johnson G, Mao Q. Dose dense chemotherapy (DDC) supported by pegfilgrastim (PEG) and an erythropoietic agent (EA) in operable breast cancer. 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 2004.
19. Fortner B, Tauer K, Zhu L, Schwartzberg L. The impact of anemia and neutropenia treatment visits on breast cancer patients and their caregivers. 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 2004
20. Johnson G, Fortner B, Moore K, Tauer K, Zhu L, Schwartzberg L. AIM Higher Working Group3. Baseline evaluation of assessment, information and management patterns in a national quality improvement project. 30th Annual Oncology Nursing Society Spring Conference, Orlando, FL, 2005.
21. Fortner B, Houts A, Johnson G, Schwartzberg L. A prospective investigation of chemotherapy-induced neutropenia (CIN) and quality of life (QoL). 41st Annual ASCO meeting, Orlando, FL, 2005.
22. Tauer K, Fortner B, Zhu L, Ma L, Schwartzberg L. Final results of the national patient impact initiative. 41st Annual ASCO meeting, Orlando, FL, 2005.
23. Blakely J, Fortner B, Kulig K, Mao Q, Wagner S, Schwartzberg L. Patient-reported symptom complaints associated with 5FU + irinotecan (IRI) or oxaliplatin (OXALI) in colorectal cancer (CRC). 41st Annual ASCO meeting, Orlando, FL, 2005.
24. Schwartzberg L, Houts A, Fortner B. Mild anemia is associated with greater symptom burden (SB) and reduced quality of life (QoL) in cancer patients. Poster presented at 41st Annual ASCO meeting, Orlando, FL, 2005.
25. Fortner B, Houts A, Johnson G, Schwartzberg L. A prospective investigation of chemotherapy-induced neutropenia (CIN) and quality of life (QoL). Poster presented at MASCC 17th International Symposium, Geneva, Switzerland, 2005.
26. Fortner B, Ma L, Zhu L, Schwartzberg L. Status of anemia management in community oncology. Poster presented at MASCC 17th International Symposium, Geneva, Switzerland, 2005.
27. Fortner B, Houts A, Johnson G, Schwartzberg L. Evaluation of the AIM Higher Initiative. Poster presented at MASCC 17th International Symposium, Geneva, Switzerland, 2005.
28. Fortner B, Kulig K, Zhu L, Wagner S, Blakely J, Schwartzberg L. A patient-reported symptom complaints associated with 5FU + irinotecan (IRI) or oxaliplatin (OXALI) in colorectal cancer (CRC). Poster presented at MASCC 17th International Symposium, Geneva, Switzerland, 2005.
29. Schwartzberg L, Kanter L, Huan R, Tauer K, Somer B. Neoadjuvant dose dense chemotherapy (NDDC) with sequential doxorubicin/cyclophosphamide (AC) followed by taxane yields high pathologic complete response (pCR) rate in II/III breast cancer. Poster presented at 27th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, 2005.
30. Fortner B, Ma L, Ling Z, Schwartzberg L. Status of Anemia Management in Community Oncology. (2005) Poster presented at 28th Annual ONS Congress, Chicago, Illinois.

CURRICULUM VITAE

Lee S. Schwartzberg, M.D.

Page 39

31. Fortner B, Kulig K, Zhu L, Wagner S, Blakely J, Schwartzberg L. A patient-reported symptom complaints associated with 5FU + irinotecan (IRI) or oxaliplatin (OXALI) in colorectal cancer (CRC). (2005) Poster presented at 28th Annual ONS Congress, Chicago, Illinois.
32. Fortner B, Kulig K, Wagner S, Schwartzberg L. Quantifying tolerability profiles with Folfox, Folfiri, and IFL+ Bevacizumab (BV) in 1st line metastatic colorectal cancer (MCRC) treatment in the community oncology setting. Poster presented at 2006 Gastrointestinal Symposium: January 26-28, San Francisco, CA. Abstract #226.
33. Schwartzberg L, Fortner B, Kulig K, Wagner S. Patient reported outcomes (PROS) in 1st line metastatic colorectal cancer (MCI) treated with Folfox or Folfiri +/- Bevacizumab. Poster presented at 2006 MASCC, June 22-25 Toronto, Canada.
34. Stepanski E, Fortner B, Burns C, Johns A, Kulig K, Schwartzberg L. Patient survey of the impact of toxicities with Folfox + Bevacizumab (BV) in 1st line metastatic colorectal cancer (MCRC) in the Community Oncology Setting. Poster presented at MASCC, June 22-25, Toronto, Canada. (2006)
35. Houts A, Fortner B, Zhu L, Schwartzberg A, Kapur D. Human Resource (HR) Costs of Chemotherapy Infusion Reactions (CIR) in Community Oncology. Poster presented at MASCC, June 22-25, Toronto, Canada (2006).
36. Schwartzberg L, Fortner B, Zhu L, Burns C, Stepanski E. Patient burden, resource utilization and treatment outcomes of major chimeric or humanized monoclonal antibody-associated infusion reactions. Poster presented at MASCC, June 22-25, Toronto, Canada (2006).
37. Schwartzberg L, Blakely J, Keaton M, Schnell F, Henry D, Epperson A, Fu D, Fortner B. A phase II trial of Pemetrexed and Gemcitabine as first line therapy for poor performance status and/or elderly patients with Stage IIIb/IV non-small cell lung cancer. Poster presented at Lilly Investigator Meeting, San Francisco, California (2006).
38. Fortner B, Schwartzberg L, Stepanski E, Houts A, Fu D, Bibbs T. Human resource (HR) implications of IV monoclonal antibody (MoAb) infusion reactions (IR): Interim data from a time and motion study. Poster presented at Chicago Supportive Oncology Conference, Chicago, Illinois (2006).
39. Fortner B, Schwartzberg L, Stepanski E, Houts A, Fu D, Bibbs T. Human resource (HR) implications of IV monoclonal antibody (MoAb) infusion reactions (IR): Interim data from a time and motion study. Poster presented at ASCO GI, January 19-21, Orlando, Florida (2006).
40. deMoor C, Fortner B, Schwartzberg L, Stepanski E, Walker M, Houts A. Human resource (HR) implications of IV monoclonal antibody (MoAB) infusion reactions (IR): Data from a time and motion study. Poster presented at Hem Onc Pharmacy Association, Denver Colorado (2007).
41. Schwartzberg L, deMoor C, Fortner B, Houts A, Stepanski E. Patient burden, provider resource utilization, and clinical consequences of severe infusion reactions associated with monoclonal antibodies. Poster presented at Hematology Oncology Pharmacy Association Meeting; 2007, June 14-16; Denver Colorado (2007).

CURRICULUM VITAE

Lee S. Schwartzberg, M.D.

Page 40

42. Fortner B, Schwartzberg L, Stepanski E, deMoor C, Walker M, Houts A, Fu D, Bibbs T. Human resource (HR) implications of IV monoclonal antibody (MoAb) infusion reactions (IR): Data from a time and motion study. Poster presented at Multinational Assoc. of Supp.Care in Cancer, St. Gallen, Switzerland (2007).
43. Schwartzberg L. Enhancing information exchange between doctors and patients in oncology practice. Annual Meeting of the American Society of Clinical Oncology; 2007; Chicago, IL; 2007.
44. Schwartzberg LS, Blakely LJ, Keaton MR, Schnell F, Henry D, Tucker S. A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIb/IV non-small cell lung cancer. In: 12th World Conference on Lung Cancer, International Association for the Study of Lung Cancer; 2007 September 2-6; Seoul, Korea; 2007.
45. Schwartzberg LS, Cobb P, Kulig K, Walker MS, Stepanski EJ, Fortner BV. Practice patterns of community based adjuvant hormonal therapy (AHT) in early stage breast cancer (ESBC). In: ASCO Breast Cancer Symposium; 2007 September 7-8; San Francisco, CA; 2007.
46. Schwartzberg LS, Houghton J, Phillips D, Stewart C, Geller J. Phase I/pharmacokinetic study of GFL: interferon gamma (IFN-gamma), bolus/infusion 5-FU and leucovorin (LV) ± Bevacizumab (BEV) for metastatic colorectal cancer (mCRC). In: American Society of Clinical Oncology, Gastrointestinal Symposium; 2007; Orlando, FL; 2007.
47. Stepanski E, Walker M, Schwartzberg L, Blakely J, Fu D, Fortner B. Prevalence of Insomnia and Associated Symptoms in Patients with Cancer. Poster presented at the American Society of Clinical Oncology Annual Meeting; 2007, June 1-5; Chicago, IL (2007).
48. Somer B, Schwartzberg L, Arena F, Mintzer D, Epperson A, Fu D, Fortner B. Phase II Trial of nabTM-Paclitaxel (Nanoparticle Albumin-bound Paclitaxel: ABX) + Capecitabine (XEL) in First Line Treatment of Metastatic Breast Cancer (MBC). Poster presented at the American Society of Clinical Oncology Annual Meeting; 2007 June 1-5; Chicago, IL (2007).
49. Schwartzberg L, Hurwitz H, Stephenson J, Kotasek D, Goldstein D, Tebbut N, et al. Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC). Poster presented at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2007.
50. Fortner B, Schwartzberg L, Stepanski E, Houts A, Fu D, Bibbs T. Human resource (HR) implications of IV monoclonal antibody (MoAb) infusion reactions (IR): Interim data from a time and motion study. Poster presented at ASCO – GI Symposium, Orlando, Florida (2007).
51. Schwartzberg LS, Tauer K, Blakely J, Johnson R, Reed J, Somer B, Wheeler B, Walker MS, Stepanski EJ, Fortner BV. Benchmarking quality oncology care in the community setting. In: San Antonio Breast Cancer Symposium; 2007 December 13 - 16; San Antonio, TX; 2007.

52. Schwartzberg LS, Tauer K, F. Schnell, Arena F, Epperson A, Fortner BV. Randomized phase II trial of two different schedules of carboplatin (C) and paclitaxel (P) +/- trastuzumab (T) as first line treatment for metastatic breast cancer (MBC). In: American Society of Clinical Oncology Breast Cancer Symposium; 2007 September 7-8; San Francisco, CA; 2007.
53. Cobb P, Hermann R, Lebos H, Tamim H, Walker M, Stepanski E, Schwartzberg L. Evidence-based treatment protocol (ETP) usage in community oncology clinics. In: Annual Meeting of the American Society of Clinical Oncology; 2008 May 30 - June 3; Chicago, IL; 2008.
54. De Moor C, Abernethy A, Sullivan P, Schwartzberg LS. Irinotecan is associated with greater symptom burden than oxaliplatin in metastatic colorectal cancer patients (mCRC) in community oncology. In: ASCO 2008 Gi Symposium; 2008 January 25 - 27; Orlando, FL; 2008.
55. Fowler ES, Schwartzberg LS. Community-based cancer genetic counseling: a unique model. In: Community Oncology Conference; 2008 February 1 - 2; Washington, DC; 2008.
56. Schwartzberg L, Stewart C, Schaiquevich P, Legenne P, Bhatt K, Johns A, Walker M. Phase I dosage-finding and pharmacokinetic (PK) study of intravenous Topotecan and oral erlotinib in patients (pts) with refractory solid tumors. Ann Mtg Am Soc Clin Onc; 2008 May 30-June .
57. Schwartzberg LS, Houghton J, Phillips D, Stewart C, Onciu M, Geller J, Walker MS. Phase II, biomarker and genomic correlative study of GFL: Interferon gamma (IFN- α), bolus/infusion 5-FU and leucovorin (LV) for metastatic colorectal cancer (mCRC). In: 2008 Annual Meeting of the American Association of Cancer Research; 2008 April 12 - 16; San Diego, CA; 2008.
58. Stepanski EJ, Walker MS, Schwartzberg LS, Blakely LJ. Relation of sleep disturbance, depression, pain, and fatigue in patients with cancer. In: Mechanisms and Treatment of Cancer-Related Symptoms Conference, MD Anderson Cancer Center; 2008 January 24 - 26; Houston, TX; 2008.
59. Blakely LJ, Somer B, Keaton M, Hermann R, Schnell F, Cobb P, Johns A, Walker M, Schwartzberg L. Neoadjuvant dose-dense sequential biweekly epirubicin (E) and cyclophosphamide (C) followed by docetaxel (T) and trastuzumab (H) for HER-2+ operable breast cancer. In: Annual Meeting of the American Society of Clinical Oncology; 2009 May 29 - June 2; Orlando, FL; 2009.
60. Hasan M, Walker M, Yim YM, Yu E, Stepanski E, Schwartzberg L. The effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients. In: San Antonio Breast Cancer Symposium; 2009 December 9 - 13; San Antonio, TX; 2009.
61. Peltz G, Girvan AC, Schwartzberg LS, Adjei A, Pennella E, Pohl G, Bendaly EA, Walker MS, Faries DE, Marciniak MD, Obasaju CK, Stepanski E. Baseline characteristics of patients enrolled in a study investigating the effects of ethnicity on treatment for non-small cell lung cancer (NSCLC) in the second-line setting with pemetrexed. In: World Conference on Lung Cancer; 2009 July 31 - August 4; San Francisco, CA; 2009.
62. Walker M, Peltz G, Houts A, Pohl G, Schwartzberg L, Stepanski E, Marciniak M. Psychosocial impact of cancer related symptoms among patients with lung cancer. In: Annual Meeting of the American Society of Clinical Oncology; 2009 May 29 - June 2; Orlando, FL; 2009.

CURRICULUM VITAE

Lee S. Schwartzberg, M.D.

Page 42

63. Walker M, Stepanski E, Reyes C, Hasan M, Schwartzberg L. Symptom burden in patients with follicular lymphoma undergoing maintenance treatment with Rituxan compared with observation. In: Annual Meeting of the American Society of Hematology; 2009 December 5 - 9; New Orleans, LA; 2009.
64. Houts A, Lalla D, Walker M, Stepanski E, Brammer M, Doan J, Schwartzberg L. Symptom burden declines when breast cancer patients treated with adjuvant trastuzumab / combination chemotherapy regimens enter trastuzumab monotherapy follow-up. In: San Antonio Breast Cancer Symposium; 2010 December 8 - 12; San Antonio, TX; 2010.
65. Lalla D, Stepanski EJ, Benn L, Brammer M, Solari PG, Walker MS, Schwartzberg; LS. Testing and treatment patterns in HER2+ breast cancer patients in the adjuvant setting. In: European Society of Medical Oncology; 2010 October 8 - 12; Milan, Italy; 2010.
66. Tillmanns TD, Lowe MP, Schwartzberg LS, Walker MS, Stepanski EJ. A phase 2 study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. In: Annual Meeting of the American Society of Clinical Oncology; 2010 June 4 - 8; Chicago, IL; 2010.
67. Walker MS, Houts AC, Hasan M, Stepanski EJ, North S, Schwartzberg LS. Engagement of lung cancer patients in quality of life assessments administered by tablet computer as a routine part of clinical care. In: Society of Behavioral Medicine; 2010 April 7 - 10, 2010; Seattle, WA; 2010.
68. Walker MS, Pohl GM, Peltz G, Stepanski EJ, Faries D, Marciniak MD, Schwartzberg LS. Treatment patterns, medical resource use, and costs associated with second line treatment of non small cell lung cancer. In: Chicago Multidisciplinary Symposium in Thoracic Oncology; 2010 December 9-11, 2010; Chicago, IL; 2010.
69. Miller PJE, Balu S, Buchner D, Walker MS, Stepanski EJ, Schwartzberg LS. Cancer patient preferences and willingness to pay for preventing chemotherapy induced nausea and vomiting in the U.S.. In: International Society for Pharmacoeconomic and Outcomes Research; 2011 May 21 - 25; Baltimore, MD; 2011.
70. Miller PJE, Balu S, Buchner D, Walker MS, Stepanski EJ, Schwartzberg LS. Willingness to Pay to Prevent Chemotherapy Induced Nausea and Vomiting. In: Annual Meeting of the American Society of Clinical Oncology; 2011 June 3 - 7; Chicago, IL; 2011.
71. Pennella E, Pohl G, Peltz G, Girvan AC, Winfree K, Martinez B, Obasaju CK, Walker MS, Stepanski E, Schwartzberg LS, Adjei A. Prospective observational comparison of outcomes in African American and Caucasian patients receiving second-line treatment with pemetrexed for advanced non-small cell lung cancer (NSCLC). In: 14th World Congress on Lung Cancer; 2011 July 3 - 7; Amsterdam, The Netherlands; 2011.
72. Schwartzberg L, Blakely J, Schnell F, Christianson D, Andrews M, Johns M, Walker M. Phase I/II trial of ixabepilone (Ixa) and dasatinib (D) for treatment of metastatic breast cancer (MBC). In: Annual Meeting of the American Association for Cancer Research; 2011 April 2 - 6; Orlando, FL; 2011.
73. Stepanski EJ, Reyes C, Walker MS, Hoang SS, Leon L, Wojtowicz-Praga S, Miller PJE, Schwartzberg LS. The association of skin rash severity with overall survival: Findings from patients receiving erlotinib for pancreatic cancer in the community setting (Rejected). In: European Society for Medical Oncology; 2011 September 23 - 27; Stockholm, Sweden; 2011.

74. Adjei AA, Pennella E, Girvan AC, Peltz G, Pohl G, Obasaju C, Winfree K, Walker MS, Stepanski EJ, Schwartzberg LS. Impact of Asian-American ethnicity on response to pemetrexed in 2nd-line non-small cell lung cancer (NSCLC). In: Annual Meeting of the American Society of Clinical Oncology; 2012 June 1 - 5; Chicago, IL; 2012.
75. Arteta-Bulos R, Miller PJE, Overbury RS, Schwartzberg A, Walker MS, Schwartzberg LS. Prognostic significance of circulating tumor cell (CTC) levels at various times during 1st and 2nd line chemotherapy for metastatic breast cancer (MBC). In: Annual Meeting of the American Society of Clinical Oncology; 2012 June 2 - 6; Chicago, IL; 2012.
76. Walker MS, Schwartzberg LS, Chen DM, Ramanan D. Treatment patterns and clinical characteristics of patients with advanced basal cell carcinoma (aBCC) in the community oncology setting. In: American Academy of Dermatology; 2012 March 6 - 20; San Diego, CA; 2012.

ORAL PRESENTATIONS

1. Fortner B, Durrence H, Houts A, Tauer K, Schwartzberg L. chemotherapy-induced anemia (CIA) occurs frequently in women receiving adjuvant/neoadjuvant chemotherapy and impacts of quality of life. Presented at the American Society of Hematology, San Diego, California (2003).
2. Schwartzberg L, Moore K, Fortner B (Speakers) and Shaughnessy A (Reviewer). Simplify in management of hematological toxicities [CD-ROM]. Training from QD Healthcare Group: Item number AE21803 (2004).
3. Johnson G, Moore K, Tauer K, Mao Q, Schwartzberg L, Fortner B, AIM Higher Working Group. Baseline evaluation of assessment, information, and management patterns in a national quality improvement project. Presented at Oncology Nursing Society Spring Conference, Orlando, Florida (2005).
4. Fortner B, Kulig K, Blakely J, Zhu L, Schwartzberg L. Patient-reported symptom complaints associated with 5-FU + Irinotecan (IIRI) or oxaliplatin (OXALI) in colorectal cancer (CRC). Presented at the ISGIO 2005 2nd Annual Gastrointestinal Oncology Conference, Arlington, Virginia (2005).
5. Fortner B, Houts A, Johnson G, Schwartzberg L. A prospective investigation of chemotherapy induced neutropenia (CIN) and quality of life (QoL). Presented at the Multinational Association of Supportive Care in Cancer 17th International Symposium, Geneva, Switzerland (2005).
6. Fortner B, Kulig K, Wagner S, Schwartzberg L. Quantifying tolerability profiles with folfox, folfiri, and IFL + bevacizumab (BV) in 1st line metastatic colorectal cancer (MCRC) treatment in the community oncology setting. Presented at the Gastrointestinal Symposium, San Francisco, California (2006).
7. Fortner B, Houts A, deMoor C, Kulig K, Schwartzberg L. Patient reported outcomes (PROS) in first line metastatic colorectal cancer (MCRC) treated with folfox or folfiri +/- bevacizumab (V) in the community oncology setting. Poster session presented at the Multinational Association of Supportive Cancer Care 17th International Symposium, Toronto, Canada (2007).

CURRICULUM VITAE

Lee S. Schwartzberg, M.D.

Page 44

8. Schwartzberg L, Fortner B, Houts A. Use of technology to enhance doctor-patient interactions. Oral presentation presented at 43rd Annual American Society of Clinical Oncology, Chicago, Illinois (2007).

BOOK CHAPTERS

1. Schwartzberg L.S. Peripheral blood stem cell mobilization in the outpatient setting. In: Wunder, Henon (eds) Peripheral Blood Stem Cell Autografts Springer-Verlag, Berlin Heidelberg, pp 177-184, 1993.
2. Weaver CH, Birch R, Schwartzberg LS, and West W. "High-dose chemotherapy and autologous stem cell transplantation for breast cancer." Buckner, Clift (eds): Technical and Biological Components of Marrow Transplantation, Kluwer Academic Publishers, Norwell, MA, pp 59-85, 1995.

INVITED PUBLISHED MANUSCRIPTS

1. Peters WP, Fay JW, Holland HK, Ahmed T, Bolwell, BJ, Wolf J, Damon L, Long G, Schwartzberg LS, Goldberg SL, Friedman DJ, Lynch JP, Weinberger BB, Taylor RF, Stadtmauer E, Rifkin RM, Broun ER, McCarthy Jr, PL, Zamkoff K, Petersen FB, Reed EC, Mills L, Schuster MW, Lazarus HH, Fruchtman SM, Hesdorffer CS, Douer D, Flomenberg J, Guarino MJ, Maziarz RT, Eifenbein GJ, LeMaistre GF, Akard L, and Cirrincione C. Autologous bone marrow transplantation in primary breast cancer: the American experience. Fifth Biennial Sandoz-Keystone Symposium on BMT; Bone Marrow Transplant, 15:S254-S259, 1995.
2. Schwartzberg L. Randomized Trial of Simultaneous vs. Sequential Doxorubicin and Docetaxel in Patients with Metastatic Breast Cancer. Cancer Conference Highlights, 4(6): 6-10, 2000.
3. Blakely LJ, Schwartzberg L, Keaton M, Schnell F, Henry D, Epperson A Walker MS. A phase II trial of Pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIb/IV non-small cell lung cancer. Lung Cancer 2009; 66:97-102.